CN103709163B - Xanthine derivative, Preparation Method And The Use - Google Patents
Xanthine derivative, Preparation Method And The Use Download PDFInfo
- Publication number
- CN103709163B CN103709163B CN201210375253.8A CN201210375253A CN103709163B CN 103709163 B CN103709163 B CN 103709163B CN 201210375253 A CN201210375253 A CN 201210375253A CN 103709163 B CN103709163 B CN 103709163B
- Authority
- CN
- China
- Prior art keywords
- methyl
- xanthine
- aminopiperidin
- formula
- chloromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 112
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 150000001875 compounds Chemical class 0.000 claims abstract description 87
- 150000003839 salts Chemical class 0.000 claims abstract description 50
- 239000003814 drug Substances 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- -1 2-buten-1-yl Chemical group 0.000 claims description 134
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 78
- 238000006243 chemical reaction Methods 0.000 claims description 64
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 48
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 38
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 32
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 24
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 22
- 235000011181 potassium carbonates Nutrition 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- IOOGOHRKXRMUEQ-UHFFFAOYSA-N 4-methyl-1-benzofuran Chemical compound CC1=CC=CC2=C1C=CO2 IOOGOHRKXRMUEQ-UHFFFAOYSA-N 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 150000002367 halogens Chemical group 0.000 claims description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- RPKWIZPGQZKQKY-UHFFFAOYSA-N 4-methyl-1-benzothiophene Chemical compound CC1=CC=CC2=C1C=CS2 RPKWIZPGQZKQKY-UHFFFAOYSA-N 0.000 claims description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 201000001421 hyperglycemia Diseases 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 229940075420 xanthine Drugs 0.000 claims description 6
- HETWIJRWPZIJSM-UHFFFAOYSA-N 7-methoxy-4-methyl-1-benzothiophene Chemical compound COC1=CC=C(C)C2=C1SC=C2 HETWIJRWPZIJSM-UHFFFAOYSA-N 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- XIMQNDKSVAPFIJ-UHFFFAOYSA-N 2-(chloromethyl)-4-methyl-1-benzothiophene Chemical compound ClCC=1SC2=C(C=1)C(=CC=C2)C XIMQNDKSVAPFIJ-UHFFFAOYSA-N 0.000 claims description 4
- GZRHFGSCUQBJHR-UHFFFAOYSA-N 7-amino-2,3-dihydroinden-1-one Chemical compound NC1=CC=CC2=C1C(=O)CC2 GZRHFGSCUQBJHR-UHFFFAOYSA-N 0.000 claims description 4
- YJWQLZYTKAVAKU-UHFFFAOYSA-N COc1ccc(C)c2cc(CCl)sc12 Chemical compound COc1ccc(C)c2cc(CCl)sc12 YJWQLZYTKAVAKU-UHFFFAOYSA-N 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000009525 Myocarditis Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 150000007960 acetonitrile Chemical class 0.000 claims description 4
- 230000002491 angiogenic effect Effects 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- IFBILVRMVDFLNK-UHFFFAOYSA-N n-(3-oxo-1,2-dihydroinden-4-yl)acetamide Chemical class CC(=O)NC1=CC=CC2=C1C(=O)CC2 IFBILVRMVDFLNK-UHFFFAOYSA-N 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 235000017550 sodium carbonate Nutrition 0.000 claims description 4
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 150000001907 coumarones Chemical class 0.000 claims description 2
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical class Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N thianaphthalene Natural products C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 17
- 239000012453 solvate Substances 0.000 abstract description 16
- 239000000651 prodrug Substances 0.000 abstract description 13
- 229940002612 prodrug Drugs 0.000 abstract description 13
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 abstract description 5
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 abstract description 5
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 241001597008 Nomeidae Species 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 71
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 66
- 239000007787 solid Substances 0.000 description 64
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 47
- 239000002904 solvent Substances 0.000 description 43
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- 235000002639 sodium chloride Nutrition 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 32
- 230000002829 reductive effect Effects 0.000 description 29
- 239000005457 ice water Substances 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 25
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 239000012074 organic phase Substances 0.000 description 22
- 238000004440 column chromatography Methods 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- 102100036968 Dipeptidyl peptidase 8 Human genes 0.000 description 17
- 102100036969 Dipeptidyl peptidase 9 Human genes 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 101000804947 Homo sapiens Dipeptidyl peptidase 8 Proteins 0.000 description 17
- 101000804945 Homo sapiens Dipeptidyl peptidase 9 Proteins 0.000 description 17
- 238000000605 extraction Methods 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- MKEXJLGKOKCUEB-CYBMUJFWSA-N tert-butyl n-[(3r)-1-(7-but-2-ynyl-3-methyl-2,6-dioxopurin-8-yl)piperidin-3-yl]carbamate Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CC#CC)C=1N1CCC[C@@H](NC(=O)OC(C)(C)C)C1 MKEXJLGKOKCUEB-CYBMUJFWSA-N 0.000 description 11
- 239000012065 filter cake Substances 0.000 description 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000011259 mixed solution Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- GUPOZVHRTJYZCX-UHFFFAOYSA-N 2-chloroethanimidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])CCl GUPOZVHRTJYZCX-UHFFFAOYSA-N 0.000 description 7
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 229960002397 linagliptin Drugs 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 6
- TUJAXGOQSUAROV-CQSZACIVSA-N tert-butyl n-[(3r)-1-[3-methyl-7-(3-methylbut-2-enyl)-2,6-dioxopurin-8-yl]piperidin-3-yl]carbamate Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CC=C(C)C)C=1N1CCC[C@@H](NC(=O)OC(C)(C)C)C1 TUJAXGOQSUAROV-CQSZACIVSA-N 0.000 description 6
- 0 C*(C)(C)C1=C(C)CC/C2=C/C=C/C(/C)=C/C(CC3)=C2C3=CCC1 Chemical compound C*(C)(C)C1=C(C)CC/C2=C/C=C/C(/C)=C/C(CC3)=C2C3=CCC1 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000001273 butane Substances 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000004260 quinazolin-2-yl group Chemical group [H]C1=NC(*)=NC2=C1C([H])=C([H])C([H])=C2[H] 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- CWTBQXKPENOVMM-UHFFFAOYSA-N ClCC=1OC2=C(C1)C(=CC=C2)C Chemical compound ClCC=1OC2=C(C1)C(=CC=C2)C CWTBQXKPENOVMM-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- VQFAIAKCILWQPZ-UHFFFAOYSA-N bromoacetone Chemical compound CC(=O)CBr VQFAIAKCILWQPZ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- QKNDSSUJHFJZTD-KTRBRXNASA-N tert-butyl n-[(3r)-1-[7-[(e)-but-2-enyl]-3-methyl-2,6-dioxopurin-8-yl]piperidin-3-yl]carbamate Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(C/C=C/C)C=1N1CCC[C@@H](NC(=O)OC(C)(C)C)C1 QKNDSSUJHFJZTD-KTRBRXNASA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- QTEQVEJOXGBDGI-UHFFFAOYSA-N 8-bromo-3-methyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(C)C2=C1NC(Br)=N2 QTEQVEJOXGBDGI-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- BXHWWPNRUOHACS-MRVPVSSYSA-N tert-butyl (3r)-1-aminopiperidine-3-carboxylate Chemical compound CC(C)(C)OC(=O)[C@@H]1CCCN(N)C1 BXHWWPNRUOHACS-MRVPVSSYSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 2
- NNQBNOWMBVHDMH-UHFFFAOYSA-N 1-(3-amino-1-benzofuran-2-yl)ethanone Chemical compound C1=CC=C2C(N)=C(C(=O)C)OC2=C1 NNQBNOWMBVHDMH-UHFFFAOYSA-N 0.000 description 2
- BAJXNWBVSDWHSY-UHFFFAOYSA-N 1-(3-amino-1-benzothiophen-2-yl)ethanone Chemical compound C1=CC=C2C(N)=C(C(=O)C)SC2=C1 BAJXNWBVSDWHSY-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GOFWLYXRIRQRBK-UHFFFAOYSA-N 2-(2-oxopropoxy)benzonitrile Chemical compound CC(=O)COC1=CC=CC=C1C#N GOFWLYXRIRQRBK-UHFFFAOYSA-N 0.000 description 2
- LCVQODRQKCOTDJ-UHFFFAOYSA-N 2-benzylsulfanylbenzonitrile Chemical compound N#CC1=CC=CC=C1SCC1=CC=CC=C1 LCVQODRQKCOTDJ-UHFFFAOYSA-N 0.000 description 2
- AOYOBWSGCQMROU-UHFFFAOYSA-N 2-sulfanylbenzonitrile Chemical compound SC1=CC=CC=C1C#N AOYOBWSGCQMROU-UHFFFAOYSA-N 0.000 description 2
- XZXZFPJEAXEESB-UHFFFAOYSA-N 8-bromo-3-methyl-7-(3-methylbut-2-enyl)purine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=C(Br)N2CC=C(C)C XZXZFPJEAXEESB-UHFFFAOYSA-N 0.000 description 2
- NKGZSVBQVPISAT-ONEGZZNKSA-N 8-bromo-7-[(e)-but-2-enyl]-3-methylpurine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=C(Br)N2C/C=C/C NKGZSVBQVPISAT-ONEGZZNKSA-N 0.000 description 2
- HFZOBQSHTNNKFY-UHFFFAOYSA-N 8-bromo-7-but-2-ynyl-3-methylpurine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=C(Br)N2CC#CC HFZOBQSHTNNKFY-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FRJYFQDYQAXYQV-SECBINFHSA-N C(C#CC)N1C(=O)NC=2N=C(NC2C1=O)N1C[C@@H](CCC1)N Chemical compound C(C#CC)N1C(=O)NC=2N=C(NC2C1=O)N1C[C@@H](CCC1)N FRJYFQDYQAXYQV-SECBINFHSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000000859 incretin Substances 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- LVVKZNOWQZDHEA-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-4-yl)acetamide Chemical compound CC(=O)NC1=CC=CC2=C1CCC2 LVVKZNOWQZDHEA-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000013641 positive control Chemical group 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- AVMHMVJVHYGDOO-NSCUHMNNSA-N (e)-1-bromobut-2-ene Chemical compound C\C=C\CBr AVMHMVJVHYGDOO-NSCUHMNNSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FPAMQDWIHLDIRH-UHFFFAOYSA-N 1-(3-amino-5-chloro-1-benzofuran-2-yl)ethanone Chemical compound C1=C(Cl)C=C2C(N)=C(C(=O)C)OC2=C1 FPAMQDWIHLDIRH-UHFFFAOYSA-N 0.000 description 1
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 1
- LNNXOEHOXSYWLD-UHFFFAOYSA-N 1-bromobut-2-yne Chemical compound CC#CCBr LNNXOEHOXSYWLD-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RXTJLDXSGNEJIT-UHFFFAOYSA-N 2,3-dihydro-1h-inden-4-amine Chemical compound NC1=CC=CC2=C1CCC2 RXTJLDXSGNEJIT-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- YDFLGIXUFCIELL-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclohexan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCC1=O YDFLGIXUFCIELL-UHFFFAOYSA-N 0.000 description 1
- MZQYOPQAFRRAJA-UHFFFAOYSA-N 2-acetyl-4-methylcyclohexan-1-one Chemical compound CC1CCC(=O)C(C(C)=O)C1 MZQYOPQAFRRAJA-UHFFFAOYSA-N 0.000 description 1
- MLNPHZNNPCQQMB-UHFFFAOYSA-N 2-acetyl-4-methylcyclopentan-1-one Chemical compound CC1CC(C(C)=O)C(=O)C1 MLNPHZNNPCQQMB-UHFFFAOYSA-N 0.000 description 1
- GUVXBBCECQQPQU-UHFFFAOYSA-N 2-acetyl-5-methylcyclohexan-1-one Chemical compound CC1CCC(C(C)=O)C(=O)C1 GUVXBBCECQQPQU-UHFFFAOYSA-N 0.000 description 1
- OEKATORRSPXJHE-UHFFFAOYSA-N 2-acetylcyclohexan-1-one Chemical compound CC(=O)C1CCCCC1=O OEKATORRSPXJHE-UHFFFAOYSA-N 0.000 description 1
- OSWDNIFICGLKEE-UHFFFAOYSA-N 2-acetylcyclopentan-1-one Chemical compound CC(=O)C1CCCC1=O OSWDNIFICGLKEE-UHFFFAOYSA-N 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-butyne Chemical compound CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- CHZCERSEMVWNHL-UHFFFAOYSA-N 2-hydroxybenzonitrile Chemical compound OC1=CC=CC=C1C#N CHZCERSEMVWNHL-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- SWBDKCMOLSUXRH-UHFFFAOYSA-N 2-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=CC=C1C#N SWBDKCMOLSUXRH-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- WNHHLYZOSOUUQW-RXMQYKEDSA-N 8-[(3r)-3-aminopiperidin-1-yl]-3,7-dihydropurine-2,6-dione Chemical compound C1[C@H](N)CCCN1C(N1)=NC2=C1C(=O)NC(=O)N2 WNHHLYZOSOUUQW-RXMQYKEDSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- XJFWGUISSCVHHL-UHFFFAOYSA-N CC(CC1)CC2=C1[I]=C(CCl)N=C2C Chemical compound CC(CC1)CC2=C1[I]=C(CCl)N=C2C XJFWGUISSCVHHL-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102100039662 Xaa-Pro dipeptidase Human genes 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- ZAFAJHDHPYDVCN-UHFFFAOYSA-N butanoic acid;phosphoric acid Chemical compound OP(O)(O)=O.CCCC(O)=O ZAFAJHDHPYDVCN-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000045598 human DPP4 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108010066823 proline dipeptidase Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a class xanthine derivative, its pharmaceutically acceptable salt, the solvate of described derivant, the solvate of pharmaceutically acceptable salt, its chemoproection form or prodrug and its production and use;Further relate to the midbody compound for preparing described xanthine derivative and described midbody compound preparation method.Described xanthine derivative and pharmaceutical composition thereof effectively suppress DPP lV activity, it is possible to for the medicine of preparation with dipeptidyl peptidase (DPP IV) relevant disease.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a novel xanthine derivative, a preparation method and application thereof, and also relates to an intermediate compound for preparing the xanthine derivative and a preparation method of the intermediate compound. The xanthine derivative and the pharmaceutical composition thereof can effectively inhibit the activity of dipeptidyl peptidase (DPP-IV) and can be used for preparing medicines for preventing or treating diseases related to DPP-IV.
Background
Dipeptidyl peptidases (Dipeptidyl peptidases) can be classified into types I, III, IV, 6,7,8, 9, 10, and the like.
Dipeptidyl peptidase-8 (DPP-8) belongs to a member of the peptidase SB9 and is a small family of Dipeptidyl peptidases. It encodes a protein gene similar to high-expression dipeptidyl peptidase-IV (DPP-IV), and the hydrolysis substrate is the same.
Dipeptidyl peptidase-9 (DPP-9) belongs to the SC class of serine proteases S9B family. It cleaves Xaa-Pro dipeptides from the N-terminus of proteins and shows proline dipeptidase activity.
Dipeptidyl peptidase-IV (DPP-IV) is a transmembrane serine proteolytic enzyme present in a variety of human tissues and organs. The single chain of human DPP-IV consists of 766 amino acids, divided into 5 structural regions: the lengths of these regions differ slightly. Soluble DPP-IV is a homodimer of approximately 210-290K and is also capable of polymerizing complexes up to 900K.
DPP-IV is combined with a membrane through a hydrophobic helix formed by a hyperglycosylation area and a cysteine enrichment area of amino acid, and a serine protease area alpha/at a carboxyl terminal is homologous with hydrolase; DPP-IV can rapidly and specifically cleave the proline or alanine residue at the second N-terminal position of the peptide chain, and its substrates include two incretins which play an important role in the signal transduction process of the immune response to type II diabetes: a glucagon-like peptide (GLP-1) fragment and a Gastric Inhibitory Peptide (GIP). GLP-1 and GIP are incretins secreted by L cells and k cells of the gastric mucosa in response to ingested carbohydrates and fats, respectively, and both regulate blood glucose concentration by acting on the pancreas to enhance glucose-induced insulin secretion, while DPP-lV hydrolyzes them to produce the corresponding N-terminal cleaved forms GLP-19-36 and GIP3-42, both of which lose insulin-inducing activity [ Expert opin. investing. drugs,2004,13(9):1091-1102 ]. Therefore, by inhibiting DDP-IV activity, it is possible to inhibit the degradation of various active peptides including GLP-1, thereby prolonging the action time, reducing the synthesis of glucose in the liver, and controlling the blood glucose level. The DPP-IV inhibitor can be used for treating, preventing or relieving diseases related to DPP-IV, such as diabetes, hyperglycemia, obesity or insulin resistance.
DPP-8 and DPP-9 are two classes of proteins with catalytic activity in the DPP family. The protein sequence of human DPP-8 and DPP-9 have 61% homology, and the protein sequence of DPP-8 and DPP-9 and DPP-4 have 26% homology. Unlike DPP-IV, DPP-8 and DPP-9 do not have extracellular catalytic domains. Wherein DPP-8 is highly expressed in activated T cells and DPP9 is highly expressed in cancer cells, skeletal muscle cells, cardiac muscle cells and liver. In both blood lymphocytes and monocytes, DPP-8 and DPP-9 are expressed. Inhibition of human DPP-8 and DPP-9 may weaken T cell activity and affect immune function. The DPP-IV inhibitor has weak DPP-8 and DPP-9 inhibitory activity and good selectivity, and has high safety and small potential toxic and side effects.
The DPP-IV inhibitor is used for inhibiting the activity of DPP-IV, can prevent the rapid degradation of degraded substances and stabilize the endogenous biological activity of the degraded substances, thereby playing a responsive therapeutic role. DPP-IV inhibitors are also thought to play a role in the cleavage of various cytokines (stimulating hematopoietic cells), growth factors and neuropeptides. For example, DDP-IV is capable of degrading the chemokines CXCL12/SDF-1a (stromal cell derived factor a), SDF is released from bone marrow stromal cells and specifically binds to receptor CXCR4 expressing hematopoietic stem/progenitor cells, CXCL12 is thought to be involved in the homing of hematopoietic stem cells [ Ludwig A, J.LeukocBiol,2002,72(1):183 + 191 ], therefore, DDP-IV inhibitors may play a decisive role in stabilizing the hematopoietic environment, mobilizing hematopoietic stem cells from the bone marrow and in hematopoietic reconstitution, and are expected to be used in the treatment of ischemic myocarditis and angiogenic diseases.
DPP-lV inhibitors have become a new direction for pharmaceutical research, and several DPP-IV inhibitors have been successfully marketed, such as Sitagliptin from Merck (WO 03004498), Vildagliptin from Novartis (WO 09819998), Saxagliptin from Bristol-Myers Squibb (WO 00168603), Alogliptin from Takeda (WO 2005095381), BI-1356 from Boehringer Ingelheim (WO 2004018468, chemical name of BI-1356: 8- [ (3R) -3-amino-1-piperidinyl ] -7- (2-butynyl) -3, 7-dihydro-3-methyl-1- [ (4-methyl-2-quinazolinyl) methyl ] -1H-purine-2, 6-dione). Although the drugs have good pharmacodynamic properties, more novel compounds with higher activity and lower toxicity are still needed to be developed, and a wider drug selection space is provided for treating DPP-IV related diseases.
Disclosure of Invention
The invention aims to provide a compound which can inhibit DPP-lV activity and can be used for treating or relieving DPP-IV related diseases.
In a first aspect, the present invention provides a xanthine derivative, a pharmaceutically acceptable salt, solvate of a pharmaceutically acceptable salt, a chemically protected form or a prodrug thereof, represented by formula I:
formula I
Wherein,
R1selected from:
R2selected from 2-buten-1-yl, 3-methyl-2-buten-1-yl or 2-butyn-1-yl;
R3、R5、R6each independently selected from hydrogen, halogen atom, straight chain or branched chain C substituted or not substituted by 1-5 halogen atoms1-6Alkyl, straight or branched C substituted or unsubstituted with 1 to 5 halogen atoms1-6Alkoxy, cyano or hydroxy;
R4selected from methyl or trifluoromethyl;
x is independently selected from O or S;
m is selected from 1 or 2.
In a specific embodiment, the xanthine derivative, pharmaceutically acceptable salt, solvate of pharmaceutically acceptable salt, chemically protected form or prodrug thereof shown in formula I according to the first aspect of the present invention,
R3、R5、R6each independently selected from hydrogen, fluorine atom, chlorine atom, bromine atom, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy, cyano or hydroxy.
Preferably R3、R5、R6Each independently selected from hydrogen, chlorine atom, methyl, methoxy and cyano.
In a specific embodiment, the xanthine derivative, pharmaceutically acceptable salt, solvate of pharmaceutically acceptable salt, chemically protected form or prodrug thereof shown in formula I according to the first aspect of the present invention,
R3selected from hydrogen, methyl, cyano;
R5selected from hydrogen, chlorine atom, methyl and methoxy;
R6selected from hydrogen, chlorine atom, methyl and methoxy.
In a specific embodiment, the xanthine derivative represented by formula I, the pharmaceutically acceptable salt, the solvate of the pharmaceutically acceptable salt, and the chemically protected form or the prodrug thereof according to the first aspect of the present invention is selected from formula I (a), formula I (b), or formula I (c):
formula I (A)
Formula I (B)
Formula I (C)
Wherein: r2、R3、R4、R5、R6M and X are as defined above.
In a specific embodiment, the xanthine derivative represented by formula I, the pharmaceutically acceptable salt, the solvate of the pharmaceutically acceptable salt, and the chemically protected form or the prodrug thereof according to the first aspect of the present invention are selected from the following compounds:
1- [ (4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (5,6,7, 8-tetrahydro-4-methylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (5,6,7, 8-tetrahydro-4-methylquinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4-methylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4-methylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4-methylbenzothiophen [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (6, 7-dihydro-4-methyl-5H-cyclopenta [ d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (5,6,7, 8-tetrahydro-4-trifluoromethylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (6-chloro-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (7-methyl-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (7-methoxy-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (5,6,7, 8-tetrahydro-4, 6-dimethylquinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (5,6,7, 8-tetrahydro-4, 7-dimethylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (5,6,7, 8-tetrahydro-4-methyl-6-cyanoquinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (6, 7-dihydro-4, 6-dimethyl-5H-cyclopenta [ d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4, 8-dimethylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4-methyl-8-chlorobenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4, 8-dimethylbenzothiophene [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4-methyl-7-methoxybenzothiophene [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine.
A second aspect of the present invention provides a process for the preparation of a xanthine derivative, a pharmaceutically acceptable salt, solvate of a pharmaceutically acceptable salt, chemically protected form or prodrug thereof, of formula I as described in the first aspect of the present invention, which comprises the steps of:
(1) r shown in formula II1Substituted halomethanes (R)1-CH2Y) and 3-methyl-7-substituted-8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl group represented by the formula IV]Xanthine to form intermediate i (a);
(2) intermediate I (a) removing tert-butyloxycarbonyl (abbreviated as Boc) in the presence of a suitable acid to obtain a compound represented by formula I;
wherein R is1、R2、R3、R4、R5、R6X, m are as defined in the first aspect of the invention; y is halogen;
the suitable acid is selected from trifluoroacetic acid, formic acid, hydrochloric acid, acetic acid, preferably trifluoroacetic acid, hydrochloric acid, most preferably trifluoroacetic acid.
In a third aspect the present invention provides a compound of formula II,
wherein: r1Selected from:
R2selected from 2-buten-1-yl, 3-methyl-2-buten-1-yl or 2-butyn-1-yl;
R3、R5、R6each independently selected from hydrogen, halogen atom, straight chain or branched chain C substituted or not substituted by 1-5 halogen atoms1-6Alkyl, straight or branched C substituted or unsubstituted with 1 to 5 halogen atoms1-6Alkoxy, cyano or hydroxy;
R4selected from methyl or trifluoromethyl;
x is independently selected from O or S;
m is selected from 1 or 2;
and when R is6When hydrogen, X is not O.
In a particular embodiment, the compound of the third aspect of the invention is selected from formula ii (a), (ii) (b) or formula ii (c):
wherein R is3、R4、R5、R6X, m are as defined in the first aspect of the invention; and when R is6When hydrogen, X is not O.
In a particular embodiment, the compound according to the third aspect of the invention is selected from the following compounds:
2-chloromethyl-4, 5-dihydrocyclopenta [ de ] quinazoline (intermediate II (B) — 1);
2-chloromethyl-5, 6,7, 8-tetrahydro-4-methylquinazoline (intermediate ii (a) -1);
2-chloromethyl-4-methylbenzofuran [3,2-d ] pyrimidine (intermediate II (C) -1);
2-chloromethyl-4-methylbenzothiophene [3,2-d ] pyrimidine (intermediate II (C) -2);
2-chloromethyl-6, 7-dihydro-4-methyl-5H-cyclopenta [ d ] pyrimidine (intermediate ii (a) -2);
2-chloromethyl-5, 6,7, 8-tetrahydro-4-trifluoromethylquinazoline (intermediate ii (a) -3);
2-chloromethyl-6-chloro-4, 5-dihydrocyclopenta [ de ] quinazoline (intermediate II (B) -2);
2-chloromethyl-7-methyl-4, 5-dihydrocyclopenta [ de ] quinazoline (intermediate II (B) -3);
2-chloromethyl-7-methoxy-4, 5-dihydrocyclopenta [ de ] quinazoline (intermediate II (B) -4);
2-chloromethyl-5, 6,7, 8-tetrahydro-4, 6-dimethylquinazoline (intermediate ii (a) -4);
2-chloromethyl-5, 6,7, 8-tetrahydro-4, 7-dimethylquinazoline (intermediate ii (a) -5);
2-chloromethyl-5, 6,7, 8-tetrahydro-4-methyl-6-cyanoquinazoline (intermediate ii (a) -6);
2-chloromethyl-6, 7-dihydro-4, 6-dimethyl-5H-cyclopenta [ d ] pyrimidine (intermediate ii (a) -7);
2-chloromethyl-4, 8-dimethylbenzofuran [3,2-d ] pyrimidine (intermediate II (C) -3);
2-chloromethyl-4-methyl-8-chlorobenzofuran [3,2-d ] pyrimidine (intermediate II (C) -4);
2-chloromethyl-4, 8-dimethylbenzothiophene [3,2-d ] pyrimidine (intermediate II (C) -5);
2-chloromethyl-4-methyl-7-methoxybenzothiophene [3,2-d ] pyrimidine (intermediate II (C) -6).
In a fourth aspect, the present invention provides a process for the preparation of a compound of formula II according to the third aspect of the invention, which process comprises the steps of:
when R is1Is composed ofWhen the temperature of the water is higher than the set temperature,
r shown in formula III (A)3Reacting substituted cycloalkanone with halogenated acetamidine hydrochloride in the presence of alkaline substances to obtain a compound shown in II (A);
the alkaline substance is selected from potassium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, potassium hydroxide, sodium methoxide and sodium ethoxide, preferably potassium carbonate, sodium carbonate and sodium hydroxide, and most preferably potassium carbonate.
When R is1Is composed ofWhen the temperature of the water is higher than the set temperature,
(1) r shown in formula III (B)5Hydrolyzing the substituted 7-acetamido-indanone to obtain 7-amino-1-indanone;
(2) cyclizing 7-amino-1-indanone and halogenated acetonitrile to obtain a compound shown in II (B).
When R is1Is composed ofWhen the temperature of the water is higher than the set temperature,
r shown in formula III (C)4Substituted benzofurans orCyclizing a benzothiophene compound and halogenated acetonitrile to obtain a compound shown in a formula II (C); wherein R is3、R4、R5、R6Is as defined in claim 1;
x is independently selected from O or S;
and when R is6When hydrogen, X is not O;
y is halogen.
In a fifth aspect, the present invention provides a pharmaceutical composition, which comprises the xanthine derivative represented by formula I, the pharmaceutically acceptable salt, the solvate of the pharmaceutically acceptable salt, the chemically protected form or the prodrug thereof, according to the first aspect of the present invention, and a pharmaceutically acceptable excipient or carrier.
In a sixth aspect, the present invention provides a xanthine derivative represented by formula I, a pharmaceutically acceptable salt, a solvate of a pharmaceutically acceptable salt, a chemically protected form, a prodrug thereof, or a composition according to the fifth aspect, wherein the xanthine derivative is used as described in the first aspect of the present invention, and the composition is used for preparing medicines for treating, preventing and relieving diseases related to DPP-iv.
In a specific embodiment of the invention, the use according to the sixth aspect of the invention is characterized in that the DPP-iv-associated disease is selected from diabetes, hyperglycemia, obesity or insulin resistance, ischemic myocarditis or angiogenic diseases; preferably, the DPP-IV related disease is selected from diabetes and hyperglycemia.
A seventh aspect of the invention provides the use of a compound according to the third aspect of the invention for the preparation of a xanthine derivative according to claim 1.
In an eighth aspect, the present invention provides a method for treating, preventing and alleviating the diseases associated with DPP-IV, which comprises administering the xanthine derivative, the pharmaceutically acceptable salt, the solvate of the pharmaceutically acceptable salt, the chemically protected form thereof and the prodrug of the xanthine derivative according to the first aspect of the present invention to a subject in need thereof.
All documents cited herein are incorporated by reference in their entirety and to the extent such documents do not conform to the meaning of the present invention, the present invention shall control.
The various terms and phrases used herein have the ordinary meaning as is known to those skilled in the art, and even then, it is intended that the present invention not be limited to the specific meanings and expressions employed herein as are inconsistent with such known meanings.
The term "halogen" or "halo" as used herein means fluoro, chloro, bromo or iodo, with the preferred halogen group being fluoro, chloro or bromo.
The term "alkyl" as used herein refers to a saturated straight or branched chain monovalent hydrocarbon radical having 1 to 6 carbon atoms (i.e., C1-6 alkyl), preferably 1 to 4 carbon atoms (i.e., C1-4 alkyl), 1 to 3 carbon atoms (i.e., C1-3 alkyl), or 1 to 2 carbon atoms (i.e., C1-2 alkyl). Examples of "alkyl" include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, 2-methylbutyl, n-hexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3-dimethylbutyl, 2-dimethylbutyl, 1-dimethylbutyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 1, 2-dimethylpropyl, and the like, and in one embodiment, alkyl is preferably selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl.
The "alkoxy" in the present invention means a saturated straight or branched chain alkoxy group having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, 1 to 3 carbon atoms or 1 to 2 carbon atoms; examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, t-butoxy, n-pentoxy, isopentoxy, 2-methylbutoxy, neopentoxy, 4-methylpentoxy, 3-methylpentoxy, 2-methylpentoxy, 1-methylpentoxy, 3-dimethylbutoxy, 2-dimethylbutoxy, 1-dimethylbutoxy, 1, 2-dimethylbutoxy, 1, 3-dimethylbutoxy, 2-ethylbutoxy, 1, 2-dimethylpropoxy, cyclopropoxy, cyclobutoxy, 1-methylcyclobutoxy, cyclopentoxy, cyclohexyloxy and the like; in one embodiment, the alkoxy group is preferably selected from methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy, n-hexoxy.
The xanthine derivative shown in the formula I comprises isomers, racemes, enantiomers, diastereomers, enantiomer enrichments, deuterons, solvates and esters thereof; the compound of the formula I and the isomer, racemate, enantiomer, diastereomer, enantiomer enrichment, deuteron, solvate and ester thereof can also form solvate, such as hydrate, alcoholate and the like. The derivatives may also be prodrugs or forms which release the active ingredient upon metabolic changes in the body. The selection and preparation of suitable prodrug derivatives is well known to those skilled in the art. Generally for the purposes of the present invention, the solvate forms of pharmaceutically acceptable solvents such as water, ethanol, etc. are equivalent to the non-solvate forms.
The compounds of formula I of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. The term "pharmaceutically acceptable salt" refers to salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. The salts may be prepared by reacting a compound of the invention with a suitable organic or inorganic acid.
Reacting the xanthine derivative shown as the formula I with an organic acid or an inorganic acid to obtain a pharmaceutically acceptable acid addition salt of the xanthine derivative, such as a hydrohalide salt, for example, a hydrochloride, a hydrobromide, a hydroiodide; other inorganic acids and their corresponding salts, such as sulfates, nitrates, phosphates, and the like; and alkyl and monoaryl sulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate; and other organic acids and their corresponding salts, such as acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, and ascorbate. Further acid addition salts of the present invention include, but are not limited to: adipate, alginate, arginate, aspartate, bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, fumarate, galactarate (galac) (from mucic acid), galacturonate, glucoheptonate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, monobutyrate phosphate, camphorate, caprylate, capryl, 2-naphthalenesulfonates, nicotinates, nitrates, oxalates, oleates, embonate salts, pectates, persulfates, phenylacetates, 3-phenylpropionates, phosphates, phosphonates and phthalates. It will be appreciated that the free base forms will generally differ somewhat in physical properties from their respective salt forms, for example solubility in polar solvents, but for the purposes of the present invention, salts are equivalent to their respective free base forms.
Preferably, the xanthine derivative represented by formula I of the present invention is reacted with the following organic acid or inorganic acid to prepare a pharmaceutically acceptable salt thereof: hydrochloric acid, sulfuric acid, phosphoric acid, malic acid, maleic acid, fumaric acid, lactic acid, benzoic acid, methanesulfonic acid, citric acid, tartaric acid, acetic acid, or trifluoroacetic acid; preferably hydrochloride, benzoate or trifluoroacetate.
The compounds of formula I of the present invention may be used alone as therapeutic agents or in combination with one or more other DPP-IV drugs having a similar or synergistic mechanism of action. Combination therapy is achieved by administering the individual therapeutic components simultaneously, sequentially or separately.
The compounds of formula I of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. The term "pharmaceutically acceptable salt" refers to salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art.
The actual dosage levels of each active ingredient in the pharmaceutical compositions of this invention can be varied so that the resulting amount of active compound is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration. Dosage levels will be selected with regard to the activity of the particular compound, the route of administration, the severity of the condition being treated and the condition and prior medical history of the patient being treated. However, it is common practice in the art to start doses of the compounds at levels below those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
When used in the above-described treatment and/or prophylaxis or other treatment and/or prophylaxis, a therapeutically and/or prophylactically effective amount of one of the compounds of the present invention may be employed in pure form or, where present, in the form of a pharmaceutically acceptable salt, ester or prodrug. Alternatively, the compounds may be administered in a pharmaceutical composition comprising the subject compound together with one or more pharmaceutically acceptable excipients. The phrase "therapeutically and/or prophylactically effective amount" of a compound of the present invention refers to a sufficient amount of the compound to treat a disorder at a reasonable benefit/risk ratio applicable to any medical treatment and/or prophylaxis. It will be appreciated, however, that the total daily amount of a compound of formula I and pharmaceutical compositions thereof of the present invention will be determined by the attending physician within the scope of sound medical judgment. For any particular patient, the specific therapeutically effective dose level will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the particular compound employed; the specific composition employed; the age, weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the particular compound employed; the duration of treatment; drugs used in combination or concomitantly with the specific compound employed; and similar factors known in the medical arts. For example, it is common in the art to start doses of the compound at levels below those required to achieve the desired therapeutic effect and to gradually increase the dose until the desired effect is achieved. In general, the dosage of the compounds of formula I of the present invention for use in mammals, especially humans, may be between 0.001 to 1000mg/kg body weight/day, such as between 0.01 to 100mg/kg body weight/day, such as between 0.01 to 10mg/kg body weight/day.
Pharmaceutical compositions containing effective amounts of the compounds of the present invention may be prepared using pharmaceutical carriers well known to those skilled in the art. The invention therefore also provides pharmaceutical compositions comprising a compound of the invention formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions may be specifically formulated for oral administration, for parenteral injection or for rectal administration in solid or liquid form.
The pharmaceutical compositions can be formulated in a variety of dosage forms for ease of administration, for example, oral formulations (e.g., tablets, capsules, solutions or suspensions); injectable formulations (e.g., injectable solutions or suspensions, or injectable dry powders, which are ready for use by addition of water for injection prior to injection). The carrier in the pharmaceutical composition comprises: binders for oral formulations (e.g., starch, typically corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone), diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycerol), lubricants (e.g., silicon dioxide, talc, stearic acid or salts thereof, typically magnesium or calcium stearate, and/or polyethylene glycol), and, if desired, disintegrating agents, such as starch, agar, alginic acid or salts thereof, typically sodium alginate, and/or effervescent mixtures, solubilizing agents, stabilizers, suspending agents, pigments, flavoring agents, and the like, preservatives for injectable formulations, solubilizers, stabilizers, and the like; bases for topical formulations, diluents, lubricants, preservatives, and the like. Pharmaceutical formulations may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically), and if certain drugs are unstable under gastric conditions, they may be formulated as enteric coated tablets.
More specifically, the pharmaceutical compositions of the present invention may be administered orally, rectally, parenterally, intravaginally, topically (such as by powders, ointments, or drops), buccally to humans and other mammals, or as an oral or nasal spray. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
Compositions suitable for parenteral injection may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous or nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), vegetable oils (such as olive oil), injectable organic esters such as ethyl oleate, and suitable mixtures thereof.
These compositions may also contain adjuvants such as preserving, wetting, emulsifying and dispersing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. Isotonic agents, for example sugars, sodium chloride and the like, are also included. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of substances delaying absorption, for example, aluminum monostearate and gelatin.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and polyoxyethylene sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
In some cases, to prolong the effect of a drug, it is desirable to slow the absorption of the drug by subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of crystalline or amorphous material which is poorly water soluble. Thus, the rate of absorption of the drug is dependent on its rate of dissolution, which in turn may be dependent on crystal size and crystal form. Alternatively, delayed absorption of a parenterally administered drug form is achieved by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms can be prepared by forming a microcapsule matrix of the drug in a biodegradable polymer such as polylactide-polyglycolide. The rate of drug release can be controlled depending on the ratio of drug to polymer and the nature of the particular polymer employed. Examples of other biodegradable polymers include polyorthoesters and polyanhydrides. Injectable depot formulations may also be prepared by embedding the drug in liposomes or microemulsions which are compatible with body tissues.
The injectable formulations can be sterilized, for example, by filtration through a bacterial filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium immediately prior to use.
The compounds of the present invention or compositions thereof may be administered orally or parenterally. The oral administration form can be tablet, capsule, coating agent, and intestinal tract external preparation such as injection and suppository. These formulations are prepared according to methods familiar to those skilled in the art. The adjuvants used for the manufacture of tablets, capsules, coatings are the customary adjuvants, such as starch, gelatin, gum arabic, silica, polyethylene glycol, solvents for liquid dosage forms, such as water, ethanol, propylene glycol, vegetable oils (e.g. corn oil, peanut oil, olive oil, etc.). The preparation containing the compound of the invention also comprises other auxiliary materials, such as a surfactant, a lubricant, a disintegrating agent, a preservative, a flavoring agent, a pigment and the like. The dosage of the compounds of formula I containing the present invention in tablets, capsules, coatings, injections and suppositories is calculated as the amount of compound present in the unit dosage form. The compound of formula I of the present invention is generally present in an amount of from 0.1 to 1000mg in a unit dosage form, preferably a unit dosage form containing from 1 to 100mg, more preferably a unit dosage form containing from 5 to 20 mg.
In particular, the present invention may provide solid dosage forms for oral administration including capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound may be mixed with at least one inert pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and gum arabic; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) humectants such as cetyl alcohol and glycerol monostearate; h) adsorbents such as kaolin and bentonite, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, buffers may also be included in the dosage forms.
Solid compositions of a similar type, using excipients such as lactose and high molecular weight polyethylene glycols and the like, can also be used as fillers in soft and hard capsules.
Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the art of pharmaceutical formulation. These solid dosage forms may optionally contain opacifying agents and may also be of such a composition that they release the active ingredient(s) only, or preferentially, at a site in the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that may be used include polymeric substances and waxes. If appropriate, the active compounds can also be formulated in microencapsulated form with one or more of the abovementioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. Liquid dosage forms may contain, in addition to the active compound, inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Oral compositions may contain, in addition to inert diluents, adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
The compounds of the present invention and compositions thereof are also contemplated for topical administration. Dosage forms for topical administration of the compounds of the present invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any required preservatives, buffers, or propellants. Ophthalmic formulations, ocular ointments, powders, and solutions are also contemplated within the scope of the invention.
The compounds of the invention may also be administered in the form of liposomes. As is well known in the art, liposomes are typically made with phospholipids or other lipid materials. Liposomes are formed from single or multiple layers of hydrated liquid crystals dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The compositions of the present invention in liposome form may contain, in addition to the compound of the present invention, stabilizers, preservatives, excipients and the like. Preferred lipids are natural and synthetic phospholipids and phosphatidylcholines (lecithins), which may be used alone or in combination. Methods of forming liposomes are well known in the art.
Detailed Description
The present invention is further illustrated by the following specific preparation examples and biological experiments; however, it should be understood that these examples and biological experiments are only for the purpose of specifically illustrating the present invention in more detail, and should not be construed as limiting the present invention in any way.
Although the materials and methods of operation are well known in the art for the purposes of this invention, the invention is nevertheless described in detail herein as is practicable. It is clear to the person skilled in the art that, in the following, the methods of operation are well known to the person skilled in the art, if not specified; the materials used are those skilled in the art which, on the basis of the published literature or the prior art, can be prepared by customary methods or are commercially available.
In the present invention, unless otherwise specified, wherein: (i) the temperature is expressed in degrees centigrade (DEG C), and the operation is carried out in a room temperature environment; said room temperature has the meaning well known in the art, in particular 10-35 ℃, preferably 15-30 ℃, most preferably 20-25 ℃; (ii) drying the organic solvent with anhydrous sodium sulfate, evaporating the solvent by a rotary evaporator under reduced pressure, and keeping the bath temperature not higher than 60 ℃; (iii) the reaction process was followed by Thin Layer Chromatography (TLC); (iv) and drying the obtained solid intermediate or final product in vacuum at the drying temperature of not higher than 60 ℃. (v) The final product has satisfactory proton NMR spectrum (1H-NMR) and Mass Spectrometry (MS) data.
Example 1:1- [ (4, 5-dihydrocyclopenta [ de ]]Quinazolin-2-yl) methyl]-3-methyl-7- (2-butyn-1-yl) -
Preparation of 8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 1)
(1) Preparation of 3-methyl-7- (2-butyn-1-yl) -8-bromoxanthine
8-bromo-3-methyl-3, 7-dihydro-purine-2, 6-dione (24.5g, 100mmol) was suspended in 150mL of N, N-dimethylformamide (abbreviated as DMF) at room temperature, diisopropylethylamine (27mL, 150mmol) was added thereto, the mixture was mechanically stirred for 10 minutes, a solution of 1-bromo-2-butyne (15g, 110mmol) in N, N-dimethylformamide (50mL) was added dropwise thereto, and after completion of the addition, the mixture was stirred at room temperature for 10 to 12 hours. After the reaction, the reaction solution was poured into ice water, and solid was precipitated by stirring, filtered, and dried under vacuum to obtain 25g of pale yellow solid with a yield of 84.1%. ES-API (M/z) [ M + H ]]+297.0,299.0。
(2) Preparation of 3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Under nitrogen, 3-methyl-7- (2-butyn-1-yl) -8-bromoxanthine (3.0g, 10mmol), potassium carbonate (2.0g, 15mmol) and 3- (R) -tert-butoxycarbonyl-aminopiperidine (2.2g, 11mmol) were added to a 50mL round-bottomed flask, 10mL of N, N-dimethylformamide was added, and the mixture was heated to 95 ℃ and stirred for 5 hours; after the reaction, the reaction solution was cooled to room temperature, and the reaction solution was poured into ice water to precipitate a solid, which was filtered and vacuum-dried to obtain a pale yellow solid 3.1g with a yield of 74.5%. ES-API (M/z) [ M + H ]]+417.1。
(3) Preparation of 4-acetamidoindane
Adding 4-aminoindan (13.5g, 101mmol) into a 500mL round-bottom flask, adding 50mL ethanol, stirring to dissolve, cooling to 0 ℃, adding 200mL ethanol solution dissolved with acetic anhydride (19mL, 201mmol), and stirring at room temperature for 12 hours; after the reaction is finished, the solvent is removed by reduced pressure evaporation to obtain17.0g of white solid, 97.1% yield. ES-API (M/z) [ M + H ]]+176.0。
(4) Preparation of 7-acetamido-1-indanone
Adding 4-acetamidoindane (5.0g, 29mmol) into a 250mL round-bottom flask, adding 150mL acetone, stirring well, adding 40mL MgSO 15% by mass4The aqueous solution was cooled to 0 ℃ and potassium permanganate (13.7g, 87mmol) was added, followed by stirring at room temperature for 15 hours. After the reaction, the reaction solution was filtered through celite, the filter cake was washed with chloroform and water in this order, the aqueous phase was separated from the filtrate, and extracted once with 50mL of chloroform, the organic phases were combined, washed once with 70mL of saturated saline, dried over anhydrous sodium sulfate for 10 hours, filtered, and the solvent was distilled off from the filtrate to obtain 4.2g of a white solid, with a yield of 76.6%. ES-API (M/z) [ M + H ]]+190.0。
(5) Preparation of 7-amino-2, 3-dihydro-1-indanone
Adding 7-acetamido-1-indanone (4.0g, 21mmol) into a 100mL round-bottom flask, then adding 50mL of 6mol/L hydrochloric acid, heating to 90 ℃, and stirring for 4 h; after the reaction, the reaction solution was cooled to 0 ℃ and the pH of the reaction solution was adjusted to 8 with 2mol/L aqueous NaOH solution, the reaction solution was extracted with ethyl acetate (30 mL) (3 times for the total extraction), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to give 2.8g of a yellow solid with a yield of 90.7%. ES-API (M/z) [ M + H ]]+148.0。
(6) Preparation of 2-chloromethyl-4, 5-dihydrocyclopenta [ de ] quinazoline (intermediate II (B) -1)
Intermediate II (B) -1
7-amino-2, 3-dihydro-1-indanone (1.5g, 10mmol) is dissolved in 20mL of 1, 4-dioxane, the solution is cooled to 10 ℃, then hydrogen chloride gas is introduced, after 2 hours, chloroacetonitrile (0.9g, 12mmol) in 1, 4-dioxane is added dropwise, and the mixture is stirred at room temperature for 5 hours. After the reaction, 50mL of ice water was added, the pH of the reaction mixture was adjusted to 8 with 2mol/L aqueous NaOH, ethyl acetate was used for extraction (30mL, 2 times of extraction), the organic phases were combined, washed with 20mL of saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated off by rotary evaporation to give 1.9g of a white solid with a yield of 92.2%. ES-API (M/z) [ M + H ]]+207.0。
(7) Preparation of 1- [ (4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Under the protection of nitrogen, 3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butyloxycarbonylamino) piperidine-1-yl]Xanthine (0.21g, 0.5mmol), potassium carbonate (0.11g, 0.8mmol) and 2-chloromethyl-4, 5-dihydrocyclopenta [ de ]]Quinazoline (0.13g, 0.6mmol) was added to a 50mL round bottom flask, 10mL of N, N-dimethylformamide was added, the temperature was raised to 90 ℃ and stirred for 5 hours; after the reaction, the reaction solution is poured into 20mL of ice water to precipitate solid, the solid is filtered, and the filter cake is purified by column chromatography to obtain 0.20g of light yellow solid, the yield is 68.5 percent, and the ES-API (M/z): M + H]+585.0。
(8) Preparation of 1- [ (4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 1)
Compound 1
1- [ (4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (0.17g, 0.3mmol) was dissolved in a mixed solution of 10mL of dichloromethane and 2mL of trifluoroacetic acid and stirred at room temperature for 1 hour. After the reaction, the solvent was distilled off, 20mL of ice water was added, the pH of the reaction solution was adjusted to 8 with 2mol/L of NaOH aqueous solution, dichloromethane was extracted (20mL, 3 times of extraction), the organic phases were combined, washed with 30mL of saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off to give a pale yellow solid, which was purified by column chromatography to give 0.10g of a white solid (Compound 1), with a yield of 68.9%.
ES-API(m/z):[M+H]+485.3。
1H-NMR(600MHz,CDCl3,ppm):7.78(d,1H),7.61(d,1H),7.37(d,1H),5.60(s,2H),4.90(d,2H),3.57-3.71(m,2H),3.55(s,3H),3.40(m,2H),3.38(m,2H),3.11(m,2H),2.93(m,1H),2.01(m,1H),1.89(m,1H),1.80(s,3H),1.73(m,1H),1.39(m,1H)。
Example 2: 1- [ (4, 5-dihydrocyclopenta [ de ]]Quinazolin-2-yl) methyl]-3-methyl-7- (3-methyl-2-butane)
Preparation of en-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthines (Compound 2)
(1) Preparation of 3-methyl-7- (3-methyl-2-buten-1-yl) -8-bromoxanthine
8-bromo-3-methyl-3, 7-dihydro-purine-2, 6-dione (24.5g, 100mmol) was suspended in 150mL of N-dimethylformamide (abbreviated as DMF) at room temperature, diisopropylethylamine (27mL, 150mmol) was added thereto, the mixture was mechanically stirred for 10 minutes, 50mL of a solution of 1-bromo-3-methyl-2-butene (16.5g, 110mmol) in N, N-dimethylformamide was added dropwise thereto, and the mixture was added dropwiseAfter the addition, the mixture is stirred for 10 to 12 hours at room temperature. After the reaction, the reaction solution was poured into 300ml of ice water to precipitate a solid, which was filtered and vacuum-dried to obtain 28.5g of a pale yellow solid with a yield of 91.1%. ES-API (M/z) [ M + H ]]+313.0,315.0。
(2) Preparation of 3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Under nitrogen, 3-methyl-7- (3-methyl-2-buten-1-yl) -8-bromoxanthine (5.0g, 16mmol), potassium carbonate (3.3g, 24mmol) and 3- (R) -tert-butoxycarbonyl-aminopiperidine (3.5g, 18mmol) were added to a 100mL round-bottomed flask, 40mL of N, N-dimethylformamide was added, and the mixture was heated to 95 ℃ and stirred for 5 hours. After the reaction, the reaction solution was poured into 50mL of ice water to precipitate a solid, which was filtered and dried in vacuo to give 5.6g of a pale yellow solid with a yield of 81.2%. ES-API (M/z) [ M + H ]]+433.1。
(3) Preparation of 1- [ (4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Under the protection of nitrogen, 3-methyl-7- (3-methyl-2-butene-1-yl) -8- [ (R) -3- (tert-butyloxycarbonylamino) piperidine-1-yl]Xanthine (0.31g, 0.7mmol), potassium carbonate (0.15g, 1.1mmol) and 2-chloromethyl-4, 5-dihydrocyclopenta [ de ]]Quinazoline (prepared according to steps (3) - (6) of example 1) (0.17g, 0.8mmol) was added to a 50mL round bottom flask, 10mL of N, N-dimethylformamide was added, and the mixture was stirred at 90 ℃ for 7 hours. After the reaction, the reaction solution was poured into ice water to precipitate a solid, which was filtered, and the filter cake was purified by column chromatography to obtain a pale yellow solid 0.32g, with a yield of 76.2%. ES-API (M/z) [ M + H ]]+601.0。
(4) Preparation of 1- [ (4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 2)
Compound 2
1- [ (4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (0.30g, 0.5mmol) was dissolved in a mixed solution of 10mL of methylene chloride and 2mL of trifluoroacetic acid and stirred at room temperature for 1 hour; after the reaction, the solvent was distilled off under reduced pressure, 20mL of ice water was added, the pH of the reaction solution was adjusted to 8 with 2mol/L of NaOH aqueous solution, dichloromethane was extracted (20mL, 3 times of extraction), the organic phases were combined, washed once with 30mL of saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give a pale yellow solid, which was purified by column chromatography to give 0.18g of a white solid (Compound 2), with a yield of 72.0%.
ES-API(m/z):[M+H]+501.4。
1H-NMR(600MHz,CDCl3,ppm):7.78(d,1H),7.61(d,1H),7.37(d,1H),5.60(s,2H),5.43(t,1H),4.73(m,2H),3.56(s,3H),3.52(m,1H),3.38-3.42(m,5H),2.97-3.09(m,2H),2.82(m,1H),2.01(m,1H),1.85(m,1H),1.70-1.75(m,7H),1.36(m,1H)。
Example 3: 1- [ (5,6,7, 8-tetrahydro-4-methylquinazolin-2-yl) methyl]-3-methyl-7- (2-butyne-1-)
Preparation of yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 3)
(1) Preparation of 2-chloromethyl-5, 6,7, 8-tetrahydro-4-methylquinazoline (intermediate II (A) -1)
Intermediate II (A) -1
2-Acetylcyclohexanone (2.8g, 20mmol), potassium carbonate (4.1g, 30mmol) and chloroacetamidine hydrochloride (2.8g, 22mmol) were added to 30mL of n-butanol, and stirred under reflux for 5 hours. After the reaction, the solvent was distilled off under reduced pressure, the residue was poured into 50mL of water, extracted with ethyl acetate (30mL, 3 times), the organic phases were combined, washed once with 30mL of saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give a yellow solid, which was purified by column chromatography (eluent: petroleum ether/ethyl acetate =9:1) to give 2.3g of a pale yellow liquid, with a yield of 58.9%. ES-API (M/z) [ M + H ]]+197.1。
(2) Preparation of 1- [ (5,6,7, 8-tetrahydro-4-methylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Under the protection of nitrogen, 3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butyloxycarbonylamino) piperidine-1-yl]Xanthine (see steps (1) - (2) of example 1 for preparation method) (0.17g, 0.4mmol), potassium carbonate (83mg, 0.6mmol) and 2-chloromethyl-5, 6,7, 8-tetrahydro-4-methyl quinazoline (0.10g, 0.5mmol) were added to a 50mL round bottom flask, 10mL of N, N-dimethylformamide was added, and the mixture was heated to 90 ℃ and stirred for 6 hours. After the reaction is finished, pouring the reaction solution into 30mL of ice water to separate out a solid, performing suction filtration, and purifying a filter cake by column chromatography to obtain 0.17g of a white solid with the yield of 73.9%. ES-API (M/z) [ M + H ]]+577.1。
(3) Preparation of 1- [ (5,6,7, 8-tetrahydro-4-methylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 3)
Compound 3
1- [ (5,6,7, 8-tetrahydro-4-methyl-quinazolin-2-yl) methyl]-3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl]Xanthine (0.15g, 0.26mmol) was dissolved in a mixed solution of 10mL of methylene chloride and 2mL of trifluoroacetic acid, and stirred at room temperature for 1 hour; after the reaction, the solvent was distilled off, 20mL of ice water was added, the pH was adjusted to 8 with 2mol/L aqueous NaOH solution, dichloromethane was extracted (20mL, 2 times of extraction), the organic phases were combined, washed with 30mL of saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give a pale yellow solid, which was purified by column chromatography to give 89mg of a white solid (Compound 3) with a yield of 71.8%. ES-API (M/z) [ M + H ]]+477.3。
1H-NMR(600MHz,CDCl3,ppm):5.32(d,2H),4.98(m,2H),3.62(m,1H),3.49-3.53(m,4H),2.74(s,2H),2.55(s,2H),2.30(s,3H),2.01(m,2H),1.88(m,1H),1.81(s,3H),1.79(m,8H)。
Example 4- [ (5,6,7, 8-tetrahydro-4-methylquinazolin-2-yl) methyl]-3-methyl-7- (3-methyl-2-
Preparation of buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 4)
(1) Preparation of 1- [ (5,6,7, 8-tetrahydro-4-methylquinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (preparation method see steps (1) - (2) of example 2) (0.26g, 0.6mmol), potassium carbonate (0.12g, 0.9mmol) and 2-chloromethyl-5, 6,7, 8-tetrahydro-4-methylquinazoline (preparation method see step (1) of example 3) (0.14g, 0.7mmol) were added to a 50mL round-bottomed flask under nitrogen protection, 10mL of N, N-dimethylformamide was added, nitrogen was replaced three times, and the mixture was stirred at 95 ℃ for 6 hours. After the reaction, the reaction solution was poured into 30mL of ice water to precipitate a solid, which was filtered, and the filter cake was purified by silica gel column to obtain a pale yellow solid (0.27g, yield 76.1%)
ES-API(m/z):[M+H]+593.1
(2) Preparation of 1- [ (5,6,7, 8-tetrahydro-4-methylquinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 4)
Compound 4
1- [ (5,6,7, 8-tetrahydro-4-methylquinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (0.25g, 0.4mmol) was dissolved in a mixed solution of 20mL of methylene chloride and 2mL of trifluoroacetic acid and stirred at room temperature for 1 hour; after the reaction, the solvent was distilled off, 20mL of ice water was added, the pH was adjusted to 8 with 2mol/L of NaOH aqueous solution, dichloromethane extraction (20mL, extraction 3 times) was performed, the organic phases were combined, 20mL of saturated brine was added for washing, anhydrous sodium sulfate was used for drying, the solvent was distilled off under reduced pressure to obtain a pale yellow solid, which was purified by a silica gel column to obtain 0.15g of a white solid (Compound 4), with a yield of 76.1%. ES-API (M/z) [ M + H ] + 493.3.
1H-NMR(600MHz,CDCl3,ppm):5.41(t,1H),5.33(s,2H),4.73(m,2H),3.53-3.56(m,4H),3.19-3.34(m,2H),2.95-3.04(m,2H),2.74(s,2H),2.55(s,2H),2.30(s,3H),2.03(m,1H),1.85(m,1H),1.71-1.79(m,11H),1.51(m,1H)。
Example 5- [ (4-methylbenzofuran [3,2-d ]]Pyrimidin-2-yl) methyl]-3-methyl-7- (2-butyne-1-)
Base) -8- (3- (R) -aminopiperidin-1-yl) Preparation of xanthine (Compound 5)
(1) Preparation of 2- (2-oxopropoxy) benzonitrile
O-hydroxybenzonitrile (12.0g, 100mmol), potassium carbonate (27.6g, 200mmol) and potassium iodide (20.0g, 120mmol) were added to 150mL acetone, stirred at room temperature for 0.5 h, bromoacetone (15.1g, 110mmol) was added, and heated under reflux for 3 h; after the reaction was completed, it was cooled to room temperature, and it was filtered with suction, the filtrate was concentrated, and the residue was added to 150mL of water, extracted with ethyl acetate (100 mL, 2 times), the organic phases were combined, washed with 100mL of saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give 16.1g of a brown solid after drying, in a yield of 92.0%. ES-API (M/z) [ M + H ] + 176.0.
(2) Preparation of 2-acetyl-3-aminobenzofuran
2- (2-oxopropoxy) benzonitrile (15.0g, 86mmol) was dissolved in 200mL of methanol, sodium methoxide (5.1g, 95mmol) was added, and the mixture was stirred at room temperature for 10-12 hours; after the reaction, the solvent was distilled off under reduced pressure, 150mL of water was added, followed by extraction with methylene chloride (100 mL, 3 times), and the organic phases were combined, washed once with 150mL of saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to give 14.1g of a yellow solid in a yield of 96.7%. ES-API (M/z) [ M + H ] + 176.1.
(3) Preparation of 2-chloromethyl-4-methylbenzofuran [3,2-d ] pyrimidine (intermediate II (c) -1)
Intermediate II (C) -1
Dissolving 2-acetyl-3-aminobenzofuran (6.0g, 34mmol) in 100mL of 1, 4-dioxane, cooling the solution to 10 ℃, introducing hydrogen chloride gas, dropwise adding a 1, 4-dioxane solution of chloroacetonitrile (3.1g, 41mmol) after 2 hours, and stirring at room temperature for 7 hours; after the reaction, 100mL of ice water was added, then the pH of the reaction solution was adjusted to 8 with 2mol/L aqueous NaOH solution, extracted with ethyl acetate (100 mL, 2 times), the organic phases were combined, washed once with 100mL of saturated saline, and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to give 5.8g of a white solid in 73.4% yield. ES-API (M/z) [ M + H ] + 233.1.
(4) Preparation of 1- [ (4-methylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Under nitrogen, 3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (0.25g, 0.6mmol), potassium carbonate (0.11g, 0.8mmol) and 2-chloromethyl-4-methylbenzofuran [3,2-d ] pyrimidine (0.16g, 0.7mmol) were added to a 50mL round-bottomed flask, 10mL of N, N-dimethylformamide was added, and the mixture was heated to 90 ℃ and stirred for 5 hours; after the reaction is finished, pouring the reaction solution into 20mL of ice water to separate out a solid, performing suction filtration, and purifying a filter cake by column chromatography to obtain 0.25g of white solid, wherein the yield of the ES-API (M/z) is 67.6 percent [ M + H ] + 613.1.
(5) Preparation of 1- [ (4-methylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 5)
Compound 5
1- [ (4-methylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (0.20g, 0.3mmol) was dissolved in a mixed solution of 20mL of dichloromethane and 2mL of trifluoroacetic acid and stirred at room temperature for 1 hour; after the reaction, the solvent was distilled off under reduced pressure, 20mL of ice water was added, the pH was adjusted to 8 with 2mol/L aqueous NaOH solution, dichloromethane was extracted (20mL, 2 times of extraction), the organic phases were combined, washed once with 20mL of saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give a pale yellow solid, which was purified by column chromatography to give 0.12g of a white solid (Compound 5) with a yield of 70.6%. ES-API (M/z) [ M + H ] + 513.2.
1H-NMR(600MHz,CDCl3,ppm):8.16(d,1H),7.60-7.64(m,2H),7.39(m,1H),5.58(s,2H),4.87-4.94(m,2H),3.70(d,1H),3.54-3.60(m,4H),3.09-3.16(m,2H),2.96(m,1H),2.74(s,3H),2.01(m,1H),1.90(m,1H),1.79(m,3H),1.74(m,1H),1.40(m,1H)。
Example 6- [ (4-methylbenzofuran [3,2-d ]]Pyrimidin-2-yl) methyl]-3-methyl-7- (3-methyl-2-
Preparation of buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 6)
(1) Preparation of 1- [ (4-methylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (0.43g, 1.0mmol, preparation method see steps (1) - (2) of example 2), potassium carbonate (0.21g, 1.5mmol) and 2-chloromethyl-4-methylbenzofuran [3,2-d ] pyrimidine (0.26g, 1.1mmol, preparation method see steps (1) - (3) of example 5) were added to a 50mL round-bottomed flask under nitrogen protection, 10mL of N, N-dimethylformamide was added, and the mixture was stirred at 90 ℃ for 8 hours; after the reaction is finished, pouring the reaction liquid into 20mL of ice water to separate out a solid, performing suction filtration, and purifying a filter cake by column chromatography to obtain 0.51g of a white solid with the yield of 81.0%. ES-API (M/z) [ M + H ] + 629.1.
(2) Preparation of 1- [ (4-methylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 6)
Compound 6
1- [ (4-methylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (0.33g, 0.5mmol) was dissolved in a mixed solution of 20mL of methylene chloride and 2mL of trifluoroacetic acid and stirred at room temperature for 1 hour; after the reaction, 20mL of ice water was added, the pH of the reaction solution was adjusted to 8 with 2mol/L NaOH aqueous solution, dichloromethane was used for extraction (20mL, 2 times of extraction), the organic phases were combined, washed once with 20mL of saturated saline, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure to give a pale yellow solid, which was purified by column chromatography to give 0.21g of a white solid (Compound 6), with a yield of 79.2%. ES-API (M/z) [ M + H ] + 529.3.
1H-NMR(600MHz,CDCl3,ppm):8.18(d,1H),7.60-7.64(m,2H),7.40(m,1H),5.61(s,2H),5.38(t,1H),4.74-4.81(m,2H),3.74(m,1H),3.65(m,1H),3.56-3.62(m,4H),3.19-3.24(m,2H),2.80(s,3H),2.14(m,1H),1.96(m,1H),1.69-1.74(m,7H),1.43(m,1H)。
Example 7- [ (4-methylbenzothiophene [3,2-d ]]Pyrimidin-2-yl) methyl]-3-methyl-7- (2-butyne-1-)
Preparation of yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 7)
(1) Preparation of 2- (benzylthio) benzonitrile
Dissolving o-nitrobenzonitrile (7.5g, 50mmol) and benzylmercaptan (6.2g, 50mmol) in 50mLN, N-dimethylformamide, cooling the solution to 0 ℃, adding dropwise 15mL of an aqueous solution of potassium hydroxide (5.0g, 90mmol), and stirring at room temperature for 2 hours; after the reaction, the reaction solution was poured into 100mL of ice water to precipitate a solid, which was filtered and dried under vacuum to obtain 9.5g of a yellow solid with a yield of 84.4%. ES-API (M/z) [ M + H ] + 226.0.
(2) Preparation of 2-mercaptobenzonitrile
Mixing AlCl3(8.6g, 65mmol) is added into 50mL of toluene, 50mL of toluene solution dissolved with 2- (benzylthio) benzonitrile (9.0g, 40mmol) is added dropwise under the protection of nitrogen, and after the dropwise addition is finished, the mixture is stirred for 48 hours at room temperature; after the reaction, 100mL of ice water was added to the reaction mixture, the organic phase was separated and washed successively with water and 5% sodium hydroxide solution (50mL) (twice), the aqueous layer was acidified to pH 3, extracted with dichloromethane (100 mL, 3 times), the organic phases were combined, washed once with 150mL of saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to give 5.0g of a brown liquid with a yield of 92.6%. ES-API (M/z) [ M + H ]]+136.0。
(3) Preparation of 2-acetyl-3-aminobenzothiophene
2-mercaptobenzonitrile (4.0g, 30mmol), potassium carbonate (8.3g, 60mmol) and potassium iodide (5.8g, 35mmol) were added to 50mL of acetone, stirred at room temperature for 0.5 h, bromoacetone (4.6g, 34mmol) was added, and the mixture was refluxed at elevated temperature for 5 h; after the reaction, it was cooled to room temperature, filtered under suction, the filtrate was concentrated, the residue was added to 100mL of water, extracted with ethyl acetate (50mL, 3 times), the organic phases were combined, washed once with 100mL of saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to give 5.0g of a brown solid with a yield of 87.7%. ES-API (M/z) [ M + H ] + 192.1.
(4) Preparation of 2-chloromethyl-4-methylbenzothiophene [3,2-d ] pyrimidine (intermediate II (C) -2)
Intermediate II (C) -2
Dissolving 2-acetyl-3-aminobenzothiophene (4.0g, 20mmol) in 100mL of 1, 4-dioxane, cooling the solution to 10 ℃, introducing hydrogen chloride gas, dropwise adding a 1, 4-dioxane solution of chloroacetonitrile (1.7g, 22mmol) after 2 hours, and stirring at room temperature for 6 hours; after the reaction, 100mL of ice water was added, the pH of the reaction mixture was adjusted to 8 with 2mol/L aqueous NaOH solution, extracted with ethyl acetate (100 mL, 2 times), the organic phases were combined, washed once with 100mL of saturated brine, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to give a yellow solid, which was purified by column chromatography (gradient elution, petroleum ether/ethyl acetate =10: 1-5: 1) to give 3.8g of a yellow solid with a yield of 76.6%. ES-API (M/z) [ M + H ] + 249.2.
(5) Preparation of 1- [ (4-methylbenzothiophen [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Under nitrogen, 3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (0.33g, 0.8mmol), potassium carbonate (0.17g, 1.2mmol) and 2-chloromethyl-4-methylbenzothiophene [3,2-d ] pyrimidine (0.22g, 0.9mmol) were added to a 50mL round-bottomed flask, 10mL of N, N-dimethylformamide was added, and the mixture was heated to 90 ℃ and stirred for 5 hours; after the reaction is finished, pouring the reaction solution into 20mL of ice water to precipitate a solid, performing suction filtration, and purifying a filter cake by using a silica gel column (gradient elution, dichloromethane/methanol =100: 1-60: 1) to obtain 0.41g of a light yellow solid, wherein the yield is 81.9%, and the ES-API (M/z): M + H ] + 629.1.
(6) Preparation of 1- [ (4-methylbenzothiophen [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 7)
Compound 7
1- [ (4-methylbenzothiophene [3,2-d ]]Pyrimidin-2-yl) methyl]-3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl]Xanthine (0.32g, 0.5mmol) was dissolved in a mixed solution of 20mL of methylene chloride and 2mL of trifluoroacetic acid, and the reaction was stirred at room temperature for 1 hour, whereupon the reaction was completed. The solvent was distilled off under reduced pressure, 20mL of ice water was added, the pH of the reaction solution was adjusted to 8 with 2mol/L aqueous NaOH solution, dichloromethane extraction (20mL, 2 times of extraction) was performed, the organic phases were combined, washed once with 20mL of saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give a yellow solid, which was purified by column chromatography to give 0.21g of a yellow solid (Compound 7) with a yield of 79.5%. ES-API (M/z) [ M + H ]]+529.2
1H-NMR(600MHz,CDCl3,ppm):8.37(d,1H),7.86(d,1H),7.61(m,1H),7.48(m,1H),5.61(s,2H),4.91(m,2H),3.72(m,1H),3.57-3.62(m,4H),3.12(m,2H),2.95(m,1H),2.74(s,3H),2.01(m,1H),1.90(m,1H),1.73-1.76(m,4H),1.39(m,1H)。
Example 8- [ (6, 7-dihydro-4-methyl-5H-cyclopenta [ d ]]Pyrimidin-2-yl) methyl]-3-methyl-7- (2-butane)
Preparation of alkyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 8)
(1) Preparation of 2-chloromethyl-6, 7-dihydro-4-methyl-5H-cyclopenta [ d ] pyrimidine (intermediate II (A) -2)
Intermediate II (A) -2
2-Acetylcyclopentanone (5.0g, 40mmol), potassium carbonate (6.9g, 50mmol) and chloroacetamidine hydrochloride (6.5g, 50mmol) were added to 50mL of n-butanol, and stirred at 120 ℃ for 5 hours; after the reaction, the solvent was removed under reduced pressure, the residue was poured into 100mL of water, extracted with ethyl acetate (50mL, 3 times), the organic phases were combined, washed once with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to give a yellow solid which was purified by column chromatography to give 1.5g of a pale yellow liquid with a yield of 20.5%. ES-API (M/z) [ M + H ]]+183.1。
(2) Preparation of 1- [ (6, 7-dihydro-4-methyl-5H-cyclopenta [ d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Under nitrogen, 3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (0.25g, 0.6mmol), potassium carbonate (0.11g, 0.8mmol) and 2-chloromethyl-6, 7-dihydro-4-methyl-5H-cyclopenta [ d ] pyrimidine (0.13g, 0.7mmol) were added to a 50mL round-bottomed flask, 10mL of N, N-dimethylformamide was added, and the mixture was stirred at 90 ℃ for 5 hours; after the reaction is finished, pouring the reaction solution into 20mL of ice water to precipitate a solid, performing suction filtration, and purifying a filter cake by column chromatography (gradient elution, dichloromethane/methanol =100: 1-50: 1) to obtain 0.29g of a white solid with the yield of 85.3%. ES-API (M/z) [ M + H ] + 563.1.
(3) Preparation of 1- [ (6, 7-dihydro-4-methyl-5H-cyclopenta [ d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 8)
Compound 8
1- [ (6, 7-dihydro-4-methyl-5H-cyclopenta [ d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (0.22g, 0.4mmol) was dissolved in a mixed solution of 10mL of methylene chloride and 2mL of trifluoroacetic acid and stirred at room temperature for 1 hour; after the reaction, the solvent was distilled off under reduced pressure, 20mL of ice water was added, the pH of the reaction solution was adjusted to 8 with 2mol/L aqueous NaOH, dichloromethane was extracted (20mL, 2 times of extraction), the organic phases were combined, washed once with 20mL of saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give a pale yellow solid, which was purified by column chromatography to give 0.14g of a pale yellow solid (compound 8) with a yield of 75.6%. ES-API (M/z) [ M + H ] + 463.2.
1H-NMR(600MHz,CDCl3,ppm):5.38(d,2H),4.98-5.05(m,2H),3.47-3.61(m,5H),2.72(m,2H),2.50(m,2H),2.28(s,3H),1.86-1.97(m,3H),1.81(s,3H),1.70-1.76(m,6H)。
Example 9: 1- [ (5,6,7, 8-tetrahydro-4-trifluoromethylquinazolin-2-yl) methyl]-3-methyl-7- (2-butane)
Preparation of alkyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 9)
(1) Preparation of 2-chloromethyl-5, 6,7, 8-tetrahydro-4-trifluoromethylquinazoline (intermediate II (A) -3)
Intermediate II (A) -3
2-trifluoroacetylcyclohexanone (5.0g, 26mmol), potassium carbonate (4.6g, 33mmol) and chloroacetamidine hydrochloride (4.0g, 31mmol) were added to 30mL of isopropanol and stirred at 50 ℃ for 3 hours; after the reaction, the solvent was distilled off under reduced pressure, the residue was poured into 100mL of water, extracted with ethyl acetate (100 mL, 2 times), the organic phases were combined, washed once with 100mL of saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give a yellow solid, which was purified by column chromatography to give 4.6g of a pale yellow solid with a yield of 70.8%. ES-API (M/z) [ M + H ] + 251.1.
(2) Preparation of 1- [ (5,6,7, 8-tetrahydro-4-trifluoromethylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Under nitrogen, 3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (0.42g, 1.0mmol), potassium carbonate (0.17g, 1.2mmol) and 2-chloromethyl-5, 6,7, 8-tetrahydro-4-trifluoromethylquinazoline (0.27g, 1.1mmol) were added to a 50mL round-bottomed flask, 10mL of N, N-dimethylformamide was added, and the mixture was stirred at 90 ℃ for 6 hours; after the reaction is finished, pouring the reaction liquid into 20mL of ice water to separate out a solid, performing suction filtration, and purifying a filter cake by column chromatography to obtain 0.56g of a white solid with the yield of 88.9%. ES-API (M/z) [ M + H ] +631.1
(3) Preparation of 1- [ (5,6,7, 8-tetrahydro-4-trifluoromethylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 9)
Compound 9
1- [ (5,6,7, 8-tetrahydro-4-trifluoromethylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine (0.32g, 0.5mmol) was dissolved in a mixed solution of 10mL of dichloromethane and 2mL of trifluoroacetic acid, and stirred at room temperature for 1 hour; after the reaction, the solvent was distilled off under reduced pressure, 20mL of ice water was added, the pH was adjusted to 8 with 2mol/L of NaOH aqueous solution, dichloromethane extraction (20mL, 2 times of extraction) was performed, the organic phases were combined, washed once with 20mL of saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give a pale yellow solid, which was purified by column chromatography to give 0.16g of a white solid (Compound 9) with a yield of 60.4%. ES-API (M/z) [ M + H ] + 531.3.
1H-NMR(600MHz,CDCl3,ppm):5.42(s,2H),4.85-4.94(m,2H),3.55-3.69(m,5H),3.18(m,2H),3.03(m,1H),2.84-2.90(m,4H),2.02(m,1H),1.90(m,1H),1.81-1.86(m,8H),1.50(m,1H)。
Example 10- [ (6-chloro-4, 5-dihydrocyclopenta [ de ]]Quinazolin-2-yl) methyl]-3-methyl-7- (2-butyne-)
Preparation of 1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 10)
(1) Preparation of 2-chloromethyl-6-chloro-4, 5-dihydrocyclopenta [ de ] quinazoline (intermediate II (B) -2)
Intermediate II (B) -2
Prepared from 4-chloro-7-amino-2, 3-dihydro-1-indanone in 86.5% yield by a method similar to that of example 1 (6). ES-API (M/z) [ M + H ]]+239.3。
(2) Preparation of 1- [ (6-chloro-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
By a method similar to example 1 (7), starting from 2-chloromethyl-6-chloro-4, 5-dihydrocyclopenta [ de ]]Quinazoline and 3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butyloxycarbonyl)Amino) piperidin-1-yl]Xanthine was prepared in 71.6% yield. ES-API (M/z) [ M + H ]]+619.3。
(3) Preparation of 1- [ (6-chloro-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 10)
Compound 10
Prepared in a similar manner to example 1 (8) from 1- [ (6-chloro-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine in 84.6% yield.
ES-API(m/z):[M+H]+519.2。
1H-NMR(600MHz,CDCl3,ppm):7.90(d,1H),7.78(s,1H),5.56(s,2H),4.91(d,2H),3.60-3.71(m,2H),3.56(s,3H),3.42(m,2H),3.39(m,2H),3.10(m,2H),2.91(m,1H),1.91-2.00(m,2H),1.81(s,3H),1.75(m,1H),1.40(m,1H)。
Example 11- [ (7-methyl-4, 5-dihydrocyclopenta [ de ]]Quinazolin-2-yl) methyl]-3-methyl-7- (3-methyl)
Preparation of the radical-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 11)
(1) Preparation of 2-chloromethyl-7-methyl-4, 5-dihydrocyclopenta [ de ] quinazoline (intermediate II (B) -3)
Intermediate II (B) -3
By a method similar to that of example 1 (6), starting from 5-methyl-7-amino-2, 3-dihydro-1-indanone preparation with a yield of 79.6%. ES-API (M/z) [ M + H ]]+219.1。
(2) Preparation of 1- [ (7-methyl-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
By a method similar to example 2 (3), starting from 2-chloromethyl-7-methyl-4, 5-dihydrocyclopenta [ de ]]Quinazoline and 3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl]Xanthine was prepared in 77.8% yield. ES-API (M/z) [ M + H ]]+615.3。
(3) Preparation of 1- [ (7-methyl-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 11)
Compound 11
Prepared in a similar manner to example 2 (4) from 1- [ (7-methyl-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine in 79.6% yield.
ES-API(m/z):[M+H]+515.3。
1H-NMR(600MHz,CDCl3,ppm):7.70(s,1H),7.27(s,1H),5.55(s,2H),5.37(s,1H),4.70-4.79(m,2H),3.50-3.55(m,4H),3.36-3.41(m,5H),2.95-3.06(m,2H),2.81(m,1H),2.51(s,3H),2.00(m,1H),1.84-1.88(m,2H),1.73(s,3H),1.71(s,3H),1.37(m,1H)。
Example 12: 1- [ (7-methoxy-4, 5-dihydrocyclopenta [ de ]]Quinazolin-2-yl) methyl]-3-methyl-7- (trans-
Preparation of 2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 12)
(1) Preparation of 3-methyl-7- (trans-2-buten-1-yl) -8-bromoxanthine
Prepared from 8-bromo-3-methyl-3, 7-dihydro-purine-2, 6-dione and (E) -1-bromo-2-butene in a yield of 92.6% by a method similar to that of example 1 (1). ES-API (M/z) [ M + H ]]+298.1,300.1。
(2) Preparation of 3-methyl-7- (trans-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Prepared in a similar manner to example 1 (2) from 3-methyl-7- (trans-2-buten-1-yl) -8-bromoxanthine and 3- (R) -tert-butoxycarbonyl-aminopiperidine in 82.8% yield. ES-API (M/z) [ M + H ]]+419.1。
(3) Preparation of 2-chloromethyl-7-methoxy-4, 5-dihydrocyclopenta [ de ] quinazoline (intermediate II (B) -4)
Intermediate II (B) -4
Prepared from 5-methoxy-7-amino-2, 3-dihydro-1-indanone in 79.6% yield by a method similar to that of example 1 (6). ES-API (M/z) [ M + H ]]+235.1。
(4) Preparation of 1- [ (7-methoxy-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
By a method similar to example 2 (3), starting from 2-chloromethyl-7-methyl-4, 5-dihydrocyclopenta [ de ]]Quinazoline with 3-methyl-7- (trans-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl]Xanthine was prepared in 76.8% yield. ES-API (M/z) [ M + H ]]+617.3。
(5) Preparation of 1- [ (7-methoxy-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 12)
Compound 12
Prepared in a similar manner to example 2 (4) from 1- [ (7-methoxy-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine in 71.6% yield.
ES-API(m/z):[M+H]+517.3。
1H-NMR(600MHz,CDCl3,ppm):7.61(s,1H),7.11(s,1H),5.56(s,2H),5.44(s,1H),5.32(s,1H),4.70-4.78(m,2H),3.81(s,3H),3.45-3.54(m,4H),3.33-3.40(m,5H),2.94-3.03(m,2H),2.82(m,1H),2.01(m,1H),1.84-1.87(m,2H),1.73(s,3H),1.36(m,1H)。
Example 13: 1- [ (5,6,7, 8-tetrahydro-4, 6-dimethylquinazolin-2-yl) methyl group]-3-methyl-7- (trans-2-)
Buten-1-yl) -8- (3- (R) -aminoPreparation of PIPERIDIN-1-YL) xanthine (Compound 13)
(1) Preparation of 2-chloromethyl-5, 6,7, 8-tetrahydro-4, 6-dimethylquinazoline (intermediate II (A) -4)
Intermediate II (A) -4
Prepared from 2-acetyl-4-methylcyclohexanone and chloroacetamidine hydrochloride in a yield of 61.6% in a similar manner to example 3 (1). ES-API (M/z) [ M + H ]]+211.1。
(2) Preparation of 1- [ (5,6,7, 8-tetrahydro-4, 6-dimethylquinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Using a method similar to that in example 3 (2), starting from 2-chloromethyl-5, 6,7, 8-tetrahydro-4, 6-dimethylquinazoline and 3-methyl-7- (trans-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl]Xanthine was prepared in 71.1% yield. ES-API (M/z) [ M + H ]]+593.3。
(3) Preparation of 1- [ (5,6,7, 8-tetrahydro-4, 6-dimethylquinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 13)
Compound 13
Prepared in a similar manner to example 3 (3) from 1- [ (5,6,7, 8-tetrahydro-4, 6-dimethylquinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine in 80.2% yield.
ES-API(m/z):[M+H]+493.3。
1H-NMR(600MHz,CDCl3,ppm):5.41-5.46(m,2H),5.32(s,2H),4.71(m,2H),3.52-3.56(m,4H),3.17-3.26(m,2H),2.94-3.04(m,2H),2.72 (s,2H),2.54(s,2H),2.31(s,3H),2.02(m,1H),1.86-1.92(m,2H),1.71-1.79(m,6H),1.35-1.40(m,4H)。
Example 14: 1- [ (5,6,7, 8-tetrahydro-4, 7-dimethylquinazolin-2-yl) methyl group]-3-methyl-7- (2-butane)
Preparation of alkyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 14)
(1) Preparation of 2-chloromethyl-5, 6,7, 8-tetrahydro-4, 7-dimethylquinazoline (intermediate II (A) -5)
Intermediate II (A) -5
Prepared from 2-acetyl-5-methylcyclohexanone and chloroacetamidine hydrochloride in a yield of 70.7% by a similar method to that of example 3 (1). ES-API (M/z) [ M + H ]]+211.1。
(2) Preparation of 1- [ (5,6,7, 8-tetrahydro-4, 7-dimethylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Using a method similar to that in example 3 (2), starting from 2-chloromethyl-5, 6,7, 8-tetrahydro-4, 7-dimethylquinazoline and 3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl]Xanthine was prepared in 72.6% yield. ES-API (m)/z):[M+H]+591.3。
(3) Preparation of 1- [ (5,6,7, 8-tetrahydro-4, 7-dimethylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 14)
Compound 14
Prepared in a similar manner to example 3 (3) from 1- [ (5,6,7, 8-tetrahydro-4, 7-dimethylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine in 77.2% yield.
ES-API(m/z):[M+H]+491.3。
1H-NMR(600MHz,CDCl3,ppm):5.30(d,2H),4.96(m,2H),3.61(m, 1H),3.58-3.56(m,4H),2.75(s,2H),2.56(s,2H),2.31(s,3H),1.92-2.00(m,3H),1.80(s,3H),1.70-1.76(m,6H),1.41(m,1H),1.26(s,3H)。
Example 15: 1- [ (5,6,7, 8-tetrahydro-4-methyl-6-cyanoquinazolin-2-yl) methyl group]-3-methyl-7-
Preparation of (trans-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 15)
(1) Preparation of 2-chloromethyl-5, 6,7, 8-tetrahydro-4-methyl-6-cyanoquinazoline (intermediate II (A) -6)
Intermediate II (A) -6
Prepared from 2-acetyl-4-cyanocyclohexanone and chloroacetamidine hydrochloride in a yield of 60.1% using a method similar to that of example 3 (1). ES-API (M/z) < M +H]+222.1。
(2) Preparation of 1- [ (5,6,7, 8-tetrahydro-4-methyl-6-cyanoquinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
Using a method similar to example 3 (2), starting from 2-chloromethyl-5, 6,7, 8-tetrahydro-4-methyl-6-cyanoquinazoline and 3-methyl-7- (trans-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl]Xanthine was prepared in 75.8% yield. ES-API (M/z) [ M + H ]]+604.3。
(3) Preparation of 1- [ (5,6,7, 8-tetrahydro-4-methyl-6-cyanoquinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 15)
Compound 15
Prepared in a similar manner to example 3 (3) from 1- [ (5,6,7, 8-tetrahydro-4-methyl-6-cyanoquinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine in a yield of 76.0%.
ES-API(m/z):[M+H]+504.3。
1H-NMR(600MHz,CDCl3,ppm):5.40-5.46(m,2H),5.31(s,2H),4.71(m,2H),3.50-3.58(m,4H),3.18-3.27(m,4H),2.82-2.90(m,3H),2.60(s,2H),2.30(s,3H),2.00(m,1H),1.84-1.92(m,2H),1.71-1.77(m,6H)。
Example 16: 1- [ (6, 7-dihydro-4, 6-dimethyl-5H-cyclopentyl)[d]Pyrimidin-2-yl) methyl]-3-methyl-7-
Preparation of (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 16)
(1) Preparation of 2-chloromethyl-6, 7-dihydro-4, 6-dimethyl-5H-cyclopenta [ d ] pyrimidine (intermediate II (A) -7)
Intermediate II (A) -7
Prepared from 2-acetyl-4-methylcyclopentanone and chloroacetamidine hydrochloride in a yield of 26.4% using a similar method to example 8 (1). ES-API (M/z) [ M + H ]]+197.1。
(2) Preparation of 1- [ (6, 7-dihydro-4, 6-dimethyl-5H-cyclopenta [ d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
By a method similar to that in example 8 (2), from 2-chloromethyl-6, 7-dihydro-4, 6-dimethyl-5H-cyclopenta [ d ]]Pyrimidine and 3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl]Xanthine was prepared in 78.1% yield. ES-API (M/z) [ M + H ]]+577.3。
(3) Preparation of 1- [ (6, 7-dihydro-4, 6-dimethyl-5H-cyclopenta [ d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 16)
Compound 16
Prepared in a similar manner to example 8 (3) from 1- [ (6, 7-dihydro-4, 6-dimethyl-5H-cyclopenta [ d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine in 74.3% yield.
ES-API(m/z):[M+H]+477.3。
1H-NMR(600MHz,CDCl3,ppm):5.30(d,2H),4.97(m,2H),3.49-3.59(m,5H),2.74(s,2H),2.55(s,2H),2.31(s,3H),2.01(m,2H),1.86(m,1H),1.81(s,3H),1.71-1.79(m,4H),1.38-1.42(m,4H)。
Example 17: 1- [ (4, 8-Dimethylbenzofuran [3,2-d ]]Pyrimidin-2-yl) methyl]-3-methyl-7- (3-methyl)
Preparation of the radical-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 17)
(1) Preparation of 2-chloromethyl-4, 8-dimethylbenzofuran [3,2-d ] pyrimidine (intermediate II (C) -3)
Intermediate II (C) -3
Prepared from 2-acetyl-3-amino-5-methylbenzofuran and chloroacetonitrile in a yield of 81.5% by a similar method to that of example 5 (3). ES-API (M/z) [ M + H ]]+247.1。
(2) Preparation of 1- [ (4, 8-dimethylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
By a method similar to that in example 6 (1), from 2-chloromethyl-4, 8-dimethylbenzofuran [3,2-d ]]Pyrimidines and 3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl group]Xanthine was prepared in 73.2% yield. ES-API (M/z) [ M + H ]]+643.3。
(3) Preparation of 1- [ (4, 8-dimethylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 17)
Compound 17
Prepared in a similar manner to example 6 (2) from 1- [ (4, 8-dimethylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine in a yield of 72.9%.
ES-API(m/z):[M+H]+543.3
1H-NMR(600MHz,CDCl3,ppm):8.01(d,1H),7.87(s,1H),7.40(d,1H),5.60(s,2H),5.36(t,1H),4.74-4.80(m,2H),3.76(m,1H),3.56-3.65(m,5H),3.18-3.22(m,2H),2.80(s,3H),2.49(s,3H),2.14(m,1H),1.98(m,1H),1.68-1.74(m,7H),1.40(m,1H)。
Example 18: 1- [ (4-methyl-8-chlorobenzofuran [3,2-d ]]Pyrimidin-2-yl) methyl]-3-methyl-7- (3-methyl)
Preparation of the radical-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (compound 18)
(1) Preparation of 2-chloromethyl-4-methyl-8-chlorobenzofuran [3,2-d ] pyrimidine (intermediate II (C) -4)
Intermediate II (C) -4
Prepared from 2-acetyl-3-amino-5-chlorobenzofuran and chloroacetonitrile in a similar manner to example 5 (3) at a yield of 76.5%. ES-API (M/z) [ M + H ]]+267.1。
(2) Preparation of 1- [ (4-methyl-8-chlorobenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
By a method similar to example 6 (1), from 2-chloromethyl-4-methyl-8-chlorobenzofuran [3,2-d]Pyrimidine and 3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl]Xanthine was prepared in 78.8% yield. ES-API (M/z) [ M + H ]]+663.2。
(3) Preparation of 1- [ (4-methyl-8-chlorobenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 18)
Compound 18
Prepared in a similar manner to example 6 (2) from 1- [ (4-methyl-8-chlorobenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine in 71.8% yield.
ES-API(m/z):[M+H]+563.2
1H-NMR(600MHz,CDCl3,ppm):8.20(d,1H),7.59(d,1H),7.47(d,1H),5.61(s,2H),5.36(t,1H),4.74-4.82(m,2H),3.77(m,1H),3.66(m,1H),3.55-3.60(m,4H),3.20-3.26(m,2H),2.81(s,3H),2.15(m,1H),1.96(m,1H),1.69-1.74(m,7H),1.42(m,1H)。
Example 19: 1- [ (4, 8-dimethylbenzothiophene [3,2-d ]]Pyrimidin-2-yl) methyl]-3-methyl-7- (2-butane)
Preparation of alkyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 19)
(1) Preparation of 2-chloromethyl-4, 8-dimethylbenzothiophene [3,2-d ] pyrimidine (intermediate II (C) -3)
Intermediate II (C) -5
Prepared from 2-acetyl-3-amino-5-methylbenzothiophene and chloroacetonitrile in a yield of 77.6% by a similar method to that of example 7 (4). ES-API (M/z) [ M + H ]]+263.0。
(2) Preparation of 1- [ (4, 8-dimethylbenzothiophene [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
By a method similar to example 7 (5), from 2-chloromethyl-4, 8-dimethylbenzothiophene [3,2-d ]]Pyrimidine and 3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl]Xanthine was prepared in 86.1% yield. ES-API (M/z) [ M + H ]]+643.3。
(3) Preparation of 1- [ (4, 8-dimethylbenzothiophene [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 19)
Compound 19
Prepared in a similar manner to example 7 (6) from 1- [ (4, 8-dimethylbenzothiophene [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine in 70.8% yield.
ES-API(m/z):[M+H]+543.2
1H-NMR(600MHz,CDCl3,ppm):8.22(d,1H),7.66(s,1H),7.45(d,1H),5.60(s,2H),4.91(m,2H),3.71(m,1H),3.56-3.61(m,4H),3.10-3.15(m,2H),2.96(m,1H),2.72(s,3H),2.46(s,3H),2.00(m,1H),1.91(m,1H),1.72-1.76(m,4H),1.38(m,1H)。
Example 20: 1- [ (4-methyl-7-methoxybenzothiophene [3,2-d ]]Pyrimidin-2-yl) methyl]-3-methyl-7-
Preparation of (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 20)
(1) Preparation of 2-chloromethyl-4-methyl-7-methoxybenzothiophene [3,2-d ] pyrimidine (intermediate II (C) -6)
Intermediate II (C) -6
Prepared from 2-acetyl-3-amino-6-methoxybenzothiophene and chloroacetonitrile in a yield of 75.8% by a similar method to that of example 7 (4). ES-API (M/z) [ M + H ]]+279.0。
(2) Preparation of 1- [ (4-methyl-7-methoxybenzothiophen [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine
By a method similar to example 7 (5), starting from 2-chloromethyl-4-methyl-7-methoxybenzothiophene [3,2-d]Pyrimidine and 3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl]Xanthine was prepared in 82.7% yield. ES-API (M/z) [ M + H ]]+659.2。
(3) Preparation of 1- [ (4-methyl-7-methoxybenzothiophen [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine (Compound 20)
Compound 20
Prepared in a similar manner to example 7 (6) from 1- [ (4-methyl-7-methoxybenzothiophene [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl ] xanthine in 76.0% yield.
E S-API(m/z):[M+H]+559.2
1H-NMR(600MHz,CDCl3,ppm):7.96(d,1H),7.51(s,1H),7.06(d,1H),5.62(s,2H),4.92(m,2H),3.82(s,3H),3.70(m,1H),3.56-3.61(m,4H),3.11-3.15(m,2H),2.94(m,1H),2.76(s,3H),2.01(m,1H),1.88(m,1H),1.72-1.76(m,4H),1.41(m,1H)。
Biological evaluation
Experimental example: determination of DPP-IV/DPP-8/DPP-9 inhibitory Activity
DPP-IV/DPP-8/DPP-9 (from BPS-Bioscience, Cat.80040, 80080, 80090) is a pure enzyme expressed using a baculovirus expression system and purified, the reaction system is performed in a buffer solution (from BPS-Bioscience, Cat.80300) at pH =7.5, and the enzyme reaction substrate is alanine-proline-7-amino-4-methylcoumarin (Ala-Pro-AMC) (from BPS-Bioscience, Cat.80305).
DPP-IV/DPP-8/DPP-9 degrades a substrate Ala-Pro-AMC to produce a product AMC (7-amino-4-methylcoumarin), which is excited by 355nm ultraviolet light to produce 460nm emitted light. The activity of DPP-IV/DPP-8/DPP-9 was determined by dynamic measurement of the rate of increase of fluorescence value of AMC at 460nm using Scanlab varioSCAN.
The determination method comprises the following steps: test compounds (compounds 1 to 20 prepared in examples 1 to 20, tested at a concentration range of 0.64 to 200nmol/L every three times of a concentration gradient), an enzyme (DPP-IV/DPP-8/DPP-9, initial concentration 0.1 ng/. mu.L) and a reaction buffer solution were mixed well, pre-incubated at 37 ℃ for 15min, an enzyme reaction substrate (initial concentration 5. mu. mol/L) was added to initiate a reaction, and a 460nm fluorescence value was continuously measured for 5 min. A blank control group without substrate, a solvent control group with DMSO (Dimethyl sulfoxide) instead of the test compound, and a positive control group of BI-1356[ see Journal of Medicinal Chemistry,2007, 26, 6450-. All final volumes were 100. mu.L. Each sample concentration was 3 replicates.
The increase in fluorescence intensity (unit: RFU/sec) in the initial period of the enzyme reaction (substrate consumption of 20% or less, substrate consumption being linear with time) was first calculated to represent the initial velocity of the enzyme (amount of product produced per unit time in the initial period of the enzyme reaction), and then the percentage of activity of each concentration group of the sample was calculated, as follows:
wherein VSample (I)Indicates the initial velocity, V, of each concentration group of the sampleDMSOThe initial velocity of the DMSO group is shown.
Using concentration value as abscissa and activity value as ordinate, then adopting GRAPHPADPRISM 5 software to make dose-effect curve fitting, calculating to obtain IC50The value is obtained. Determination of the biological Activity of a part of the Compounds of the formula IThe test results are shown in Table 1.
TABLE 1 inhibitory Activity of some of the Compounds of formula I on DPP-IV/DPP-8/DPP-9
Note: "/" indicates that the compound was not tested for efficacy
Among them, BI-1356 was proposed as a positive control for the test. The data in the table 1 show that the compound of the invention has better inhibitory activity to DPP-IV, and the selectivity to DPP-8 and DPP-9 is equivalent to that of BI-1356; particularly, DPP-IV inhibitory activity of the compound 1, the compound 2, the compound 3, the compound 5, the compound 7 and the compound 10 is obviously stronger than that of BI-1356 and is 2-10 times stronger than that of BI-1356, so that the compound has better biological activity.
In conclusion, the compound shown in the formula I can well inhibit DPP-IV, and can be used for treating, preventing and relieving diseases related to DPP-IV, such as diabetes, hyperglycemia, obesity or insulin resistance, ischemic myocarditis or angiogenic diseases.
Claims (20)
1. A xanthine derivative of formula I or a pharmaceutically acceptable salt thereof:
wherein,
R1selected from:
R2selected from 2-buten-1-yl, 3-methyl-2-buten-1-yl or 2-butyn-1-yl;
R3、R5、R6each independently selected from hydrogen, halogen atom, straight chain or branched chain C substituted or not substituted by 1-5 halogen atoms1-6Alkyl, straight or branched C substituted or unsubstituted with 1 to 5 halogen atoms1-6Alkoxy, cyano or hydroxy;
R4selected from methyl or trifluoromethyl;
x is independently selected from O or S;
m is selected from 1 or 2.
2. The xanthine derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein,
R3、R5、R6each independently selected from hydrogen, fluorine atom, chlorine atom, bromine atom, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy, cyano or hydroxy.
3. The xanthine derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein,
R3、R5、R6each independently selected from hydrogen, chlorine atom, methyl, methoxy and cyano.
4. The xanthine derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein,
R3selected from hydrogen, methyl, cyano;
R5selected from hydrogen, chlorine atom, methyl and methoxy;
R6selected from hydrogen, chlorine atom, methyl and methoxy.
5. A xanthine derivative of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the xanthine derivative of formula I is selected from formula I (a), formula I (b), or formula I (c):
wherein: r2、R3、R4、R5、R6M, X are as defined in claim 1.
6. The xanthine derivative of formula I, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 5, which is selected from the following compounds:
1- [ (4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (5,6,7, 8-tetrahydro-4-methylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (5,6,7, 8-tetrahydro-4-methylquinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4-methylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4-methylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4-methylbenzothiophen [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (6, 7-dihydro-4-methyl-5H-cyclopenta [ d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (5,6,7, 8-tetrahydro-4-trifluoromethylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (6-chloro-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (7-methyl-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (7-methoxy-4, 5-dihydrocyclopenta [ de ] quinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (5,6,7, 8-tetrahydro-4, 6-dimethylquinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (5,6,7, 8-tetrahydro-4, 7-dimethylquinazolin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (5,6,7, 8-tetrahydro-4-methyl-6-cyanoquinazolin-2-yl) methyl ] -3-methyl-7- (trans-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (6, 7-dihydro-4, 6-dimethyl-5H-cyclopenta [ d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4, 8-dimethylbenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4-methyl-8-chlorobenzofuran [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (3-methyl-2-buten-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4, 8-dimethylbenzothiophene [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine;
1- [ (4-methyl-7-methoxybenzothiophene [3,2-d ] pyrimidin-2-yl) methyl ] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine.
7. A process for the preparation of a xanthine derivative of formula I or a pharmaceutically acceptable salt thereof, which process comprises the steps of:
(1) r shown in formula II1Substituted methyl halide and 3-methyl-7-substituted-8- [ (R) -3- (tert-butoxycarbonylamino) piperidin-1-yl group represented by the formula IV]Xanthine reaction to produce intermediate i (a);
(2) removing tert-butyloxycarbonyl from the intermediate I (a) in the presence of a suitable acid to obtain a compound represented by formula I;
wherein R is1、R2、R3、R4、R5、R6X, m is as defined in claim 1; y is halogen;
the suitable acid is selected from trifluoroacetic acid, formic acid, hydrochloric acid, acetic acid.
8. The method of claim 7 wherein the suitable acid is selected from the group consisting of trifluoroacetic acid and hydrochloric acid.
9. The method of claim 7 wherein the suitable acid is trifluoroacetic acid.
10. A compound of the formula II,
wherein: r1Selected from:R3、R5、R6each independently selected from hydrogen, halogen atom, straight chain or branched chain C substituted or not substituted by 1-5 halogen atoms1-6Alkyl, straight or branched C substituted or unsubstituted with 1 to 5 halogen atoms1-6Alkoxy, cyano or hydroxy;
R4selected from methyl or trifluoromethyl;
x is independently selected from O or S;
y is halogen;
m is selected from 1 or 2;
and when R is6When hydrogen, X is not O.
11. The compound of formula II according to claim 10, which is selected from II (a), formula II (b) or formula II (c):
wherein R is3、R4、R5、R6X, m is as defined in claim 1; and when R is6When hydrogen, X is not O.
12. The compound of formula II according to claim 10, selected from the following compounds:
2-chloromethyl-4, 5-dihydrocyclopenta [ de ] quinazoline (intermediate II (B) — 1);
2-chloromethyl-5, 6,7, 8-tetrahydro-4-methylquinazoline (intermediate ii (a) -1);
2-chloromethyl-4-methylbenzothiophene [3,2-d ] pyrimidine (intermediate II (C) -2);
2-chloromethyl-6, 7-dihydro-4-methyl-5H-cyclopenta [ d ] pyrimidine (intermediate ii (a) -2);
2-chloromethyl-5, 6,7, 8-tetrahydro-4-trifluoromethylquinazoline (intermediate ii (a) -3);
2-chloromethyl-6-chloro-4, 5-dihydrocyclopenta [ de ] quinazoline (intermediate II (B) -2);
2-chloromethyl-7-methyl-4, 5-dihydrocyclopenta [ de ] quinazoline (intermediate II (B) -3);
2-chloromethyl-7-methoxy-4, 5-dihydrocyclopenta [ de ] quinazoline (intermediate II (B) -4);
2-chloromethyl-5, 6,7, 8-tetrahydro-4, 6-dimethylquinazoline (intermediate ii (a) -4);
2-chloromethyl-5, 6,7, 8-tetrahydro-4, 7-dimethylquinazoline (intermediate ii (a) -5);
2-chloromethyl-5, 6,7, 8-tetrahydro-4-methyl-6-cyanoquinazoline (intermediate ii (a) -6);
2-chloromethyl-6, 7-dihydro-4, 6-dimethyl-5H-cyclopenta [ d ] pyrimidine (intermediate ii (a) -7);
2-chloromethyl-4, 8-dimethylbenzofuran [3,2-d ] pyrimidine (intermediate II (C) -3);
2-chloromethyl-4-methyl-8-chlorobenzofuran [3,2-d ] pyrimidine (intermediate II (C) -4);
2-chloromethyl-4, 8-dimethylbenzothiophene [3,2-d ] pyrimidine (intermediate II (C) -5);
2-chloromethyl-4-methyl-7-methoxybenzothiophene [3,2-d ] pyrimidine (intermediate II (C) -6).
13. A process for preparing a compound of formula II, comprising the steps of:
when R is1Is composed ofWhen the temperature of the water is higher than the set temperature,
r shown in formula III (A)3Reacting substituted cycloalkanone with halogenated acetamidine hydrochloride in the presence of alkaline substances to obtain a compound shown in II (A);
the alkaline substance is selected from potassium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, potassium hydroxide, sodium methoxide and sodium ethoxide;
when R is1Is composed ofWhen the temperature of the water is higher than the set temperature,
(1) r shown in formula III (B)5Hydrolyzing the substituted 7-acetamido-indanone to obtain 7-amino-1-indanone;
(2) cyclizing 7-amino-1-indanone and halogenated acetonitrile to obtain a compound shown in II (B);
when R is1Is composed ofWhen the temperature of the water is higher than the set temperature,
r shown in formula III (C)6Cyclizing the substituted benzofuran or benzothiophene compound and halogenated acetonitrile to obtain a compound shown as a formula II (C); wherein R is3、R4、R5、R6Is as defined in claim 1;
x is independently selected from O or S;
and when R is6When hydrogen, X is not O;
y is halogen.
14. The process of claim 13, wherein the alkaline substance is potassium carbonate, sodium hydroxide.
15. The process of claim 13, wherein the basic material is potassium carbonate.
16. A pharmaceutical composition comprising a xanthine derivative of formula I, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 6, and a pharmaceutically acceptable excipient or carrier.
17. Use of a xanthine derivative of formula I, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 6, or a composition according to claim 16, for the preparation of a medicament for the treatment, prevention and alleviation of DPP-iv related diseases.
18. The use according to claim 17, wherein the DPP-iv-related disease is selected from diabetes, hyperglycemia, obesity, insulin resistance, ischemic myocarditis, or angiogenic diseases.
19. The use according to claim 17, wherein the DPP-iv-related disease is selected from diabetes and hyperglycemia.
20. Use of a compound of formula II as defined in any one of claims 10 to 12 for the preparation of a xanthine derivative as defined in claim 1.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210375253.8A CN103709163B (en) | 2012-09-29 | 2012-09-29 | Xanthine derivative, Preparation Method And The Use |
PCT/CN2013/083096 WO2014048243A1 (en) | 2012-09-29 | 2013-09-09 | Xanthine derivative, preparation method and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210375253.8A CN103709163B (en) | 2012-09-29 | 2012-09-29 | Xanthine derivative, Preparation Method And The Use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103709163A CN103709163A (en) | 2014-04-09 |
CN103709163B true CN103709163B (en) | 2016-12-21 |
Family
ID=50386973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210375253.8A Active CN103709163B (en) | 2012-09-29 | 2012-09-29 | Xanthine derivative, Preparation Method And The Use |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103709163B (en) |
WO (1) | WO2014048243A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6840931B2 (en) * | 2015-03-09 | 2021-03-10 | 東ソー株式会社 | Method for Producing Fused Ring Aromatic Compound |
CN104844602B (en) * | 2015-04-14 | 2018-07-20 | 威海迪素制药有限公司 | A kind of preparation method of Li Gelieting |
CN107216340B (en) * | 2016-03-22 | 2021-05-04 | 中国科学院上海药物研究所 | Salt form of DPPIV inhibitor and preparation method thereof |
CN107216339B (en) * | 2016-03-22 | 2021-05-04 | 中国科学院上海药物研究所 | Polymorphism of DPPIV inhibitor maleate and preparation method thereof |
CN110894198B (en) * | 2018-09-13 | 2022-12-02 | 齐鲁制药有限公司 | Xanthine compound and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1675212A (en) * | 2002-08-21 | 2005-09-28 | 贝林格尔英格海姆法玛两合公司 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
CN1980930A (en) * | 2004-02-18 | 2007-06-13 | 贝林格尔·英格海姆国际有限公司 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and the use in the form of a DPP-IV inhibitor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1514552A4 (en) * | 2002-06-06 | 2008-04-02 | Eisai R&D Man Co Ltd | Novel fused imidazole derivative |
IT1403282B1 (en) * | 2010-12-23 | 2013-10-17 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF LINAGLIPTIN |
-
2012
- 2012-09-29 CN CN201210375253.8A patent/CN103709163B/en active Active
-
2013
- 2013-09-09 WO PCT/CN2013/083096 patent/WO2014048243A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1675212A (en) * | 2002-08-21 | 2005-09-28 | 贝林格尔英格海姆法玛两合公司 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
CN1980930A (en) * | 2004-02-18 | 2007-06-13 | 贝林格尔·英格海姆国际有限公司 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and the use in the form of a DPP-IV inhibitor |
Non-Patent Citations (1)
Title |
---|
RN:949877-52-5;ACS;《STN REGISTRY》;20071010;第1-3页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103709163A (en) | 2014-04-09 |
WO2014048243A1 (en) | 2014-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3188730B1 (en) | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 | |
CN103709163B (en) | Xanthine derivative, Preparation Method And The Use | |
CN101362765A (en) | 5,7-diaminopyrazolo '4,3-d!pyrimidines with PDE-5 inhibiting activity | |
EP2593456B1 (en) | Aldose reductase inhibitors and uses thereof | |
EA030115B1 (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
RU2672582C2 (en) | Bicyclic inhibitors | |
EP2786998B1 (en) | Thienyl [3, 2-d]pyrimidin-4-one compounds, preparation method, pharmaceutical compositions and use thereof | |
CN102827170A (en) | Active treatment compositions and use method thereof | |
JP2006045156A (en) | Condensed pyrazole derivative | |
CN104039784A (en) | Substituted annellated pyrimidine and the use thereof | |
US20170022218A1 (en) | Condensed 5-oxazolidinone derivative | |
CN103459382B (en) | For suppressing the heterocyclic compound of PASK | |
CN111434662B (en) | Haloallylamine compound and application thereof | |
JPWO2005021550A1 (en) | Bicyclic pyrazole derivatives | |
EP3541376A1 (en) | Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 | |
JPWO2005051949A1 (en) | New condensed imidazole derivatives | |
EP2513108B1 (en) | Novel (heterocycle/condensed piperidine)-(piperazinyl)-1-alcanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors | |
JP2022543515A (en) | plasma kallikrein inhibitor | |
US8785477B2 (en) | Hexahydropyrrolo[3,4-b]pyrrole derivatives, preparation methods and pharmaceutical uses thereof | |
US20240158390A1 (en) | Other heteroaromatic compounds having activity against rsv | |
CN103420981A (en) | Substituted-pyrrolidinyl-contained thiomorpholine compounds | |
WO2023155004A1 (en) | Pyrazolopyrimidines, compositions comprising them and uses thereof | |
WO2018102256A1 (en) | Pyrrolidinone compounds | |
CN110256420B (en) | Tetrahydropyridopyrimidine derivatives, their preparation and use | |
CN114671878B (en) | Substituted nitrogen-containing bicyclic compounds and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201021 Address after: 570314 -A, Nanhai Avenue, national hi tech Development Zone, Hainan, Haikou, 273 Patentee after: QILU PHARMACEUTICAL (HAINAN) Co.,Ltd. Address before: 250100 No. 243 industrial North Road, Licheng District, Shandong, Ji'nan Patentee before: Qilu Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |